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人生重要的不是所站的位置，而是所朝的方向。 
The important thing in life is not where you stand, but rather 
where you are heading. 
Chinese saying 
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ABSTRACT 
Spinal cord injury (SCI) is a devastating condition without a cure. The SCI process comprises 
an initially mechanical trauma and a secondary cascade of events including a robust 
inflammatory and immune response. Experimental neural cell therapy in animal models have 
presented a series of beneficial effects such as neuroprotection, cell replacement, remyelination 
and axon regeneration. However, it is still to a large degree unclear how the host immune and 
nervous system respond to and interact with human donor neural stem/progenitor cells (NPCs). 
Therefore, features of human NPCs and their effects on potential host responder cells such as 
lymphocytes, microglia and spinal cord neural cells were studied in vitro and in vivo. 
Features of two relevant types of donor human NPCs: human embryonic stem cell-
derived NPCs (hESC-NPCs) and human fetal spinal cord-derived NPCs (hfNPCs), cultured 
under equivalent conditions were evaluated. hESC-NPCs and hfNPCs presented relatively 
similar expression patterns of human leukocyte antigen, co-stimulatory and adhesion molecules 
and were mostly not affected by two inflammatory cytokines of interest in SCI. Unstimulated 
hfNPCs secreted more transforming growth factor-β (TGF-β) but similar level of interleukin 
(IL)-10 compared to hESC-NPCs. In contrast to hfNPCs, hESC-NPCs showed increased 
release of TGF-β and IL-10 under in vitro conditions mimicking inflammation. Both human 
NPCs reduced an alloreaction between non-compatible allogeneic peripheral blood 
mononuclear cells (PBMCs) and up-regulated CD4+CD25+forkhead box P3+ T cells, identified 
as induced regulatory T cells. However, hESC-NPCs but not hfNPCs dose-dependently 
triggered allogeneic PBMC proliferation, which may be at least partly due to TGF-β signaling. 
To conclude, differences in immunocompetence and interaction with allogeneic PBMCs were 
observed between hESC-NPCs and hfNPCs. These differences may be crucial for the host 
response in neural cell therapy. 
To study the interaction between human NPCs and allogeneic microglia, an in vitro co-
culture model was employed. The presence of microglia enhanced the survival and proliferation 
of hfNPCs, but hindered their differentiation. In the presence of hfNPCs, the survival, 
proliferation and phagocytosis of human microglia was increased. The expression of the 
neuroimmune regulatory protein CD200 on hfNPCs, and the CD200 receptor on microglia, 
were enhanced in co-cultures, accompanied by increased secretion of TGF-β, indicating an anti-
inflammatory feature of the co-cultures. To conclude, in this model of the naïve encounter of 
human donor NPCs with host microglial cells, the interplay between human NPCs and 
allogeneic microglia significantly affected their respective proliferation and phenotype. The 
neural cell and microglial interaction presented features that may benefit host neuroprotection 
and repair. 
To further study host responses in neural cell therapy, hfNPCs were xenotransplanted 
to rats with severe or moderate SCI with or without immunosuppression. hfNPCs, expanded in 
vitro for 5 passages (NPC-P5) and grafted acutely to severe SCI rats, were completely rejected. 
In acute transplantation of NPC-P0 and delayed transplantation of NPC-P5 to rats with 
moderate SCI, a complete rejection occurred in 40 and 33%, respectively. Locomotor function 
was not significantly different between groups, indicating that neither transplantation nor 
rejection altered functional outcome during the 6-week long study. Host microglial activation at 
the SCI epicenter was reduced in hfNPC transplantation groups compared to lesion alone in 
both a xeno- and allotransplantation model. In conclusion, human neural transplantation may 
result in a host rejection but still reduce the microglial response at the SCI epicenter. 
Finally, the injured spinal cord response to human NPCs was evaluated in two different 
rat SCI models and a human allograft in vitro model. Spinal cord-derived hfNPCs (SC-NPCs) 
transplanted subacutely after contusion injury improved host locomotor function. In a 
compression SCI model, acutely or subacutely grafted SC-NPCs, but not chronically 
transplanted SC-NPCs or subacutely grafted forebrain-derived hfNPCs, enhanced functional 
recovery. Four months after transplantation, the number of surviving host spinal cord neurons 
was highest in acutely and subacutely transplanted groups, accompanied by the best hindlimb 
function. This suggests that transplanted SC-NPCs improve functional recovery by a 
neuroprotective effect. In addition, grafted SC-NPCs reduced the percentage of injury-induced 
apoptotic cells in a human organotypic spinal cord culture system. 
In summary, human NPCs exert immunomodulatory and neuroprotective effects in SCI 
models. The human NPC origin, the host injury severity and the time point of neural cell 
therapy in SCI may affect the host–donor interaction and host response. With increased 
knowledge and awareness of these factors, human neural cell therapies for SCI can be improved 
to achieve higher therapeutic efficacy. 
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1 INTRODUCTION 
1.1 Spinal cord injury (SCI) – an overview 
Spinal cord injury (SCI), due to sudden and/or sustained trauma, is a devastating 
condition including functional deficits as well as emotional, social, and financial 
burdens. Physical disruption of spinal cord circuitries, descending and ascending axons 
results in motor and sensory dysfunction, often including spasticity, neuropathic pain, 
paresthesia and autonomic dysreflexia. Furthermore, SCI also leads to an increased risk 
of cardiovascular complications, osteoporosis, pressure ulcers, and urinary tract 
infections (Hagen et al. 2011). 
 
Worldwide, the reported annual incidences of SCI range from 2.3 in Canada to 83 in 
Alaska per million inhabitants (Hagen et al. 2012). Two recent Scandinavian studies 
have revealed trends of increased incidence rates over the past few decades (Ahoniemi 
et al. 2008; Hagen et al. 2010). SCI victims are predominantly male (80.7%) and nearly 
half are injured between the ages of 16 and 30 (National Spinal Cord Injury Statistical 
Center, USA, 2012; Levi et al. 1995). In USA, the most common causes of traumatic 
SCI are traffic accidents, falls, violence (primarily gun shot wounds) followed by 
sports-related injuries (National Spinal Cord Injury Statistical Center, USA, 2012). In 
Europe, violence causes a smaller proportion of the injuries compared to the USA. 
Cervical SCIs account for up to 75% of the total number of SCIs, followed by thoracic 
and lumbar SCIs (Devivo 2012; Hagen et al. 2012). 
 
The SCI process includes two sequential phases. First, the initially mechanical trauma 
that causes an immediate structural and physiological disruption of axons, neural cell 
damage and vascular disruption at the site of injury within seconds (Hulsebosch 2002). 
Microvascular tearing leads to hemorrhage, edema, ischemia, substantially reducing 
tissue perfusion and delivery of oxygen and nutrition to tissues, all of which further 
exacerbate the neural injury (Tator and Fehlings 1991). A secondary degenerative 
phase is initiated by a cascade of vascular, biochemical and cellular processes that can 
last from days to years (Sekhon and Fehlings 2001). The ischemia and edema at the 
injury epicenter develop and spread to the adjacent tissues within 24-48 hours after the 
initial trauma (Tator and Fehlings 1991). The hemorrhage and microvascular 
reperfusion increase the level of free radicals, contributing to a progressive oxidation of 
fatty acids in cellular membranes (named lipid peroxidation). The oxidative stress 
  10 
disables key mitochondrial respiratory chain enzymes, alters DNA and associated 
proteins and inhibits sodium-potassium ATPase, inducing metabolic collapse and 
further cell death by necrosis and/or apoptosis (Lewen et al. 2000). Compromised 
membrane integrity and calcium transporters rapidly lead to increased intracellular 
calcium concentrations. Extracellular accumulation of excitatory neurotransmitters such 
as glutamate occurs rapidly after injury in response to ischemia and malfunctional 
cellular transporters. Activation of ionotropic glutamate receptors increases intracellular 
accumulation of calcium further, which triggers a multitude of events that also end in a 
progressive cell death and tissue damage (Park et al. 2004). The loss of 
oligodendrocytes, which are particularly vulnerable to excitotoxicity, results in 
demyelination of axons and conduction deficits (Hulsebosch 2002). The breakdown of 
the blood-brain barrier facilitates the infiltration of peripheral immune cells (e.g. 
neutrophils, monocytes, macrophages and lymphocytes). The infiltration of immune 
cells initiates the inflammatory response in the injured spinal cord, accompanied by the 
intraspinal microglial activation and the production of pro-inflammatory cytokines 
(Trivedi et al. 2006). In addition, reactive astrocytes around the lesion together with 
invading meningeal fibroblasts, vascular endothelial cells, microglia, oligodendrocyte 
precursors and myelin debris form a non-permissive glial scar, sealing the lesion from 
the intact spinal cord (Fawcett and Asher 1999; Fitch et al. 1999). Recently, Göritz et 
al. also demonstrated that pericytes after SCI gave rise to stromal cells that even 
outnumbered the astrocytes in the scar (Goritz et al. 2011). A scar in the injured spinal 
cord hinders re-growth and repair of injured axons by production of inhibitory 
molecules such as chondroitin sulphate proteoglycans (CSPGs); on the other hand, it 
can also re-establish the physical and chemical integrity of the injured spinal cord and 
minimize the spread of cellular damage (Rolls et al. 2009; Silver and Miller 2004). 
 
1.2 Inflammation and immune responses after SCI 
SCI initiates robust inflammatory and immune responses, which persists for several 
weeks to months after the lesion. The response is characterized by infiltration of 
peripherally derived immune cells (such as neutrophils, monocytes, macrophages and 
lymphocytes), activation of glial cells (microglia and astrocytes) within the spinal 
cord itself, and the release of cytokines (Beck et al. 2010; Fleming et al. 2006; 
Popovich et al. 1997). The inflammatory and immune reaction in SCI not only 
contributes to exacerbate the injury and damage healthy tissues, but is also a critical 
host defense mechanism to eliminate invading pathogens and to clear debris. 
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Neutrophils in SCI 
Neutrophils are the first peripheral immune cells to arrive at the injury site after SCI, 
reaching a peak at three days post-injury but with an additional second peak several 
weeks later (Carlson et al. 1998; Fleming et al. 2006; Kigerl et al. 2006). They are 
particularly abundant around the central gray matter hemorrhagic and necrotic areas 
(Fleming et al. 2006). The recruitment of neutrophils from peripheral blood may be 
enhanced by adhesion molecule expression (e.g. transmembrane intracellular 
adhesion molecule and platelet–endothelial cell adhesion molecule) on the cellular 
membrane to guide them to the injury site. Neutrophils are involved in the 
phagocytosis of tissue debris and the modulation of the inflammatory response by 
releasing proteases (e.g. matrix metalloproteinases (MMPs) and elastase), free 
radicals and cytokines (Trivedi et al. 2006). For example, MMP-9 is reported to 
cleave myelin basic protein (MBP) and contributes to demyelination of healthy axons 
(Noble et al. 2002), early secondary tissue damage and hemorrhagic injury (Fleming 
et al. 2006). However, neutrophils do not only have detrimental bystander effects. A 
recent study showed that depleting neutrophils by selective antibody treatment in SCI 
mice resulted in a marked increase in tissue damage and impaired functional 
recovery, confirming also the protective and regulatory role of neutrophils in SCI 
(Stirling et al. 2009). 
 
Macrophages and microglia in SCI 
Monocytes enter the injury site and quickly differentiate into macrophages (Blight 
1985; Popovich et al. 1997). Resident microglia respond to an injury in the spinal 
cord rapidly, within minutes (Fleming et al. 2006). Recruited macrophages and 
activated microglia contribute to the secondary tissue damage and inflammatory 
response in part through the production of toxic mediators (e.g. tumor necrosis factor 
(TNF)-α, interleukin (IL)-1β and IL-6) and enzymes (e.g. inducible nitric oxide 
synthase (iNOS) and cyclooxygenase-2 (COX-2)) (David and Kroner 2011; Jones et 
al. 2005; Pais et al. 2008). Upon exposure to necrotic neural cells, the up-regulation 
of major histocompatibility complex (MHC) class II and co-stimulatory molecules on 
macrophages and microglia enables them to present antigen to CD4+ T cells and to 
participate in the adaptive immune response (Pais et al. 2008). Activated 
macrophages and microglia are efficient phagocytes and are capable of clearing 
debris from the injured spinal cord (Smith et al. 1998). Cytokines (e.g. IL-1, TNF-α) 
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derived from activated microglia may also contribute to oligodendrocyte 
proliferation, remyelination, axon re-growth and revascularization at the injury site 
(Jones et al. 2005). Other soluble factors, such as transforming growth factor (TGF)-
β, brain-derived neurotrophic factor (BDNF), glial cell-derived neurotrophic factor 
(GDNF) and neurotrophin (NT)-3, produced by microglia may help tissue repair by 
enhancing axonal sprouting, suppressing macrophage activation and blocking the 
production of reactive oxygen intermediates and inflammatory cytokines (Batchelor 
et al. 1999; David and Kroner 2011). Macrophages and microglia can also increase 
the uptake of extracellular glutamate through transporter proteins such as GLAST and 
GLT-1 (Gras et al. 2012; van Landeghem et al. 2001). Activated macrophages and 
microglia are highly plastic cells, and can play a neurotoxic and/or neuroprotective 
role (David and Kroner 2011). The neurotoxic activities are usually associated with 
the “classical activation (via Toll-like receptors or interferon (IFN)-γ)” M1 
phenotype, and their release of pro-inflammatory cytokines, such as TNF-α and IL-1, 
contributing to neuronal dysfunction and cell death (Block and Hong 2005). While 
the protective activities are associated with the “alternative activation (by IL-4 or IL-
13)” M2 phenotype, and the production of neuroprotective substances, such as anti-
inflammatory cytokines and neurotrophic factors, promoting tissue repair by blocking 
the production of reactive oxygen intermediates and pro-inflammatory cytokines 
(David and Kroner 2011). Kigerl and colleagues reported the co-existence of M1 and 
M2 macrophages in the contused mice spinal cord, showing that M1 macrophage 
response was rapidly induced, neurotoxic and maintained at the injury sites, while the 
response of M2 macrophages was smaller, transient and promoted axon re-growth 
and limited the secondary inflammatory-mediated injury (Kigerl et al. 2009). 
 
Lymphocytes in SCI 
Lymphocytes are activated by neuroantigens that are released into the blood and 
lymphatic system (Ankeny and Popovich 2009). T cells progressively increase in 
number in parallel with the activation of microglia and influx of peripheral 
macrophages during the first week after SCI. The T cell number remains elevated for 
long (Ankeny and Popovich 2009; Sroga et al. 2003). Activated T cells contribute to 
microvascular injury, axonal impairment, neurotoxicity and regulation of macrophage 
functions (Jones et al. 2005). Chronically activated T cells participate in the 
pathological fibrosis and scarring (Wynn 2004). A subpopulation of T cells is 
activated by myelin protein from necrotic and apoptotic neural cells, called MBP-
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reactive T cells. MBP-reactive T cells are reported to exacerbate axonal injury, 
demyelination and functional loss after experimental SCI (Jones et al. 2004). MBP-
reactive T cells isolated from SCI rats induce transient paralysis and inflammation 
when injected to uninjured rats (Popovich et al. 1996). However, Schwartz and 
Kipnis proposed that trauma-induced activation of MBP-reactive T cells is a 
physiological rather than a pathological consequence of injury and should be boosted 
to achieve neuroprotection (Schwartz and Kipnis 2001). T cells can also produce 
neurotrophic factors and immunosuppressive cytokines to inhibit macrophage 
produced inflammatory cytokines (e.g. TNF-α) and promote the production of 
immunomodulatory cytokines such as TGF-β (Jones et al. 2005). SCI could also 
result in the activation of B cells and pathogenic autoantibody production within both 
cerebrospinal fluid and the spinal cord parenchyma (Ankeny et al. 2009). Injury-
activated B cells could influence axonal regeneration and oligodendrocyte survival 
through the increased production of autoantibodies that are specific to myelin protein 
(Huang et al. 1999; Saltzman et al. 2013). 
 
Reactive astrocytes in SCI 
SCI triggers astrocytes to undergo phenotypic and morphological changes including 
hypertrophy, elevated proliferation and increased expression of intermediate 
filaments such as glial fibrillary acidic proteins (GFAP), nestin, and vimentin (Silver 
and Miller 2004). Reactive astrocytes could exert both detrimental and beneficial 
effects by releasing both pro- and anti-inflammatory cytokines such as TNF-α, IFN-γ, 
IL-1, IL-6 and TGF-β to regulate inflammation and secondary injury mechanisms 
(Karimi-Abdolrezaee and Billakanti 2012). Reactive astrocytes contribute to the 
production of inhibitory extracellular matrix components such as CSPGs, tenascins 
and collagen that obstruct axonal elongation and sprouting (Fitch et al. 1999; Shibuya 
et al. 2009). Reactive astrocytes play crucial roles in SCI repair with protective 
properties: reconstructing damaged blood-brain barrier, limiting infiltration of 
peripheral leukocytes and activation of resident microglia, modulating blood flow, 
up-take of excessive glutamate and producing antioxidants (i.e. glutathione) against 
oxidative stress (Karimi-Abdolrezaee and Billakanti 2012; Leal-Filho 2011). Reactive 
astrocytes can potentially promote tissue repair and regeneration by up-regulation of 
fibroblast growth factor (FGF)-2 and S100β, which are exclusive to reactive 
astrocytes but not activated macrophages and microglia, in the injured spinal cord (do 
Carmo Cunha et al. 2007). Ablation of reactive astrocytes in SCI animals caused 
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substantial vasogenic edema and widespread inflammation and tissue degeneration 
(Faulkner et al. 2004). 
 
Complement system in SCI 
The complement system plays a crucial role in the recruitment of mononuclear cells 
and macrophages (C3a and C5a) and in the deposition of the cytotoxic pore-forming 
membrane attack complexes (C5–C9) on the cell surface (David et al. 2012). 
Complement proteins are elevated in SCI patients (Rebhun et al. 1991). SCI causes the 
locally increased synthesis of complement proteins, which deposit on neurons, axons 
and oligodendrocytes (Anderson et al. 2004). Galvan et al. reported that the activation 
of the classical complement pathway via C1q is detrimental for tissue damage and 
functional recovery after SCI (Galvan et al. 2008). Mice deficient in C3 showed 
significant enhancement in functional recovery, tissue sparing and less necrosis, 
demyelination and neutrophil infiltration after SCI (Qiao et al. 2006). These results 
indicate that the complement contributes to secondary damage after SCI. 
 
 
Fig.1. Schematic figure showing the role of the main immune cells and mediators 
involved in the inflammatory and immune response after SCI. 
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1.3 Treatment strategies for SCI 
Below, some important and promising treatment strategies for SCI will be mentioned 
without the possibility to make the list complete within the frame of this thesis 
summary. 
 
General management 
Traumatic SCI usually includes fractures and ligament ruptures of the vertebral column, 
as a result, minor movements or manipulations of the unstable columnar region in the 
neck or back can worsen an already existing injury in the spinal cord. Thus, the first 
important pre-hospital action is immobilization of the patient using a cervical collar, 
head immobilization, and a spinal board (Ahn et al. 2011). Transportation of patients 
with acute SCI to hospital should occur without delay, and early transfer is preferable 
as it decreases overall mortality and complications (Ahn et al. 2011; Divanoglou et al. 
2010a; Parent et al. 2011). Protection of airway, acute control of blood loss and 
maintenance of systemic blood pressure and oxygenation are basic managements for 
patients with acute SCI to limit the extent of injury and to prevent further complications 
(Stahel et al. 2012). Recent studies also have suggested early and prompt transfer of 
SCI patients to specialized SCI care centers to decrease mortality rates and medical 
complications (Divanoglou et al. 2010a; Divanoglou et al. 2010b; Fehlings et al. 2011). 
 
Surgical strategies 
Often a surgical decompression with or without arthrodesis is performed to prevent 
additional neurological damage after an SCI (van Middendorp et al. 2012). Clinical 
trials have indicated a benefit by early decompression therapy, based on an operational 
definition of “early” being less than 24 hours after SCI (Hawryluk et al. 2008). New 
surgical treatments are under development, such as building bridges with bioengineered 
scaffold in combination with cell transplantation or neurotrophic factor delivery to 
provide guidance cues for possible re-establishment of damaged axonal connections 
(Kubinova and Sykova 2012). 
 
Physical means 
Positive results have been reported after hyperbaric oxygen treatment in SCI by 
partially compensating the reduction of oxygen perfusion (Cristante et al. 2012; Kelly 
et al. 1972). Physical exercise including walking, bicycling and step training on a 
treadmill can result in increased functional recovery, coordination and neurological 
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performance due to remodeling of intrinsic neural circuit and elevated release of 
intrinsic growth factors (Ferreira et al. 2010; Foret et al. 2010; Houle and Cote 2013). 
Functional electrical stimulation is applied for SCI patients, and has resulted in 
increased muscle mass, enhanced cardiovascular function, improved bowel function, 
decreased spasticity and improved body weight-supported walking (Gater et al. 2011). 
Other strategies such as hypothermia are still under evaluation (Hawryluk et al. 2008). 
 
Neuroprotective agents 
Significant efforts have been devoted to try to limit the evolution of secondary damage 
after a SCI. High dose methylprednisolone has been relatively widely applied in SCI 
after reports on its multiple protective effects, including anti-inflammatory action, 
increase of blood flow, stabilization of cell membranes, inhibition of lipid peroxidation 
and reduction of glutamate and free radical release (Bracken et al. 1992). However, a 
limited if any functional improvement has been observed in the clinic by 
methylprednisolone. Therefore, the deleterious side effects from corticosteroids have 
led many centers to avoid routine usage of corticoids, particularly methylprednisolone, 
for SCI patients (Domingo et al. 2012). Gangliosides induce neuronal regeneration, and 
increase the in vitro formation and growth of neurites as well as the establishment of 
new functional connections. Improvements of motor and sensory functions have also 
been reported in SCI patients who received GM1 ganglioside compared to placebos 
(Hawryluk et al. 2008). The combination of GM1 and physical therapy improved motor 
scores, walking velocity and distance over a placebo or physical therapy alone in 
individuals with incomplete SCI (Domingo et al. 2012; Rabchevsky et al. 2011). 
Another potent neuroprotective drug is the tetracycline antibiotic minocycline, that 
decreases glutamate-mediated excitotoxicity, acts as an immunomodulator by blocking 
microglial activation and reduces oligodendrocyte death and axonal dieback in rodent 
models of SCI (Rabchevsky et al. 2011). Other immunosuppressants (e.g. cyclosporine 
A, rapamycin) were also found to exert neuroprotective effects by inhibiting microglial 
proliferation and secretion of neurotoxic substances and thereby improving 
preservation of CNS structures (Hailer 2008). Blocking pro-inflammatory cytokines 
(e.g. TNF-α, IL-1, IL-6) in the injured spinal cord to limit secondary damage and to 
decrease the lesion size is yet another strategy that has resulted in reports of functional 
improvements (Lavine et al. 1998; Mukaino et al. 2010; Nesic et al. 2001; Okada et al. 
2004; Vogt et al. 2008). 
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Blocking inhibitory factors 
Intact and injured CNS myelin contains several axon growth inhibitory molecules 
(including Nogo-A, myelin-associated glycoprotein and oligodendrocyte myelin 
glycoprotein). Multiple therapies have been developed to inhibit CSPGs, target and 
overcome myelin related inhibitors for axon growth. Antibodies against Nogo-A may 
promote growth of corticospinal tract axons in rats and monkeys after SCI, and even in 
SCI patients according to a recently performed clinical trial with improved outcome 
(Pernet and Schwab 2012). The delivery of the enzyme chondroitinase ABC, which 
inhibits the synthesis of CSPGs, alone or in the combination with physical exercise or 
cell transplantation, has been reported to increase regeneration of injured axons and to 
improve functional recovery in experimental models (Bradbury and Carter 2011; Chau 
et al. 2004). In addition, inhibition of Rho-kinase has resulted in protective effects and 
accelerated functional recovery in experimental acute SCI (McKerracher and Higuchi 
2006). 
 
Neurotrophic factors 
Neurotrophic factors modulate the survival of neural cells, synaptic plasticity and 
neurotransmission. Exogenous administration of neurotrophic factors has been 
proposed as a potential therapeutic approach for SCI. BDNF, GDNF, NT-3, NT-4 and 
nerve growth factor have all demonstrated therapeutic potential in experimental SCI 
models (Thuret et al. 2006). However, neurotrophic factors alone seem not to be 
sufficient in assisting injured neurons to overcome the inhibitory environment present 
in the lesioned spinal cord (Schwab et al. 2006). Functional recovery has been 
achieved by experimental cell transplantation, with olfactory ensheathing cells 
(OECs), bone marrow mesenchymal/stromal cells (BMSCs), NPCs or ESCs, that 
were genetically modified to produce neurotrophic factors (Thuret et al. 2006). 
 
Cell-based transplantation 
Cell-based therapy is another promising strategy for SCI, and pre-clinical researchers 
have demonstrated that cell-based transplantation can ameliorate secondary events 
and restore lost tissues. Different sources and types of cells/tissues, including spinal 
cord and peripheral nerve tissues, stem/progenitor cells (ESCs, induced pluripotent 
stem cells (iPSCs), NPCs or BMSCs) and non-stem derived cells (Schwann cells, 
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OECs and activated macrophages), have been and/or are being tested in preclinical 
stage and clinical trials for SCI (Tetzlaff et al. 2011). 
 
Grafts of human fetal spinal cord tissues have been reported to survive up to at least 12 
months after transplantation and withdrawal of immunosuppressant, and to obliterate 
parts of the posttraumatic cyst in patients (Falci et al. 1997; Wirth et al. 2001). David 
and Aguayo demonstrated that injured CNS axons were able to regenerate for long 
distances toward the targeted area with a supportive substrate such as a segment of 
peripheral nerve (David and Aguayo 1981). Cheng et al. transplanted multiple 
autologous intercostal nerve grafts combined with acidic FGF to bridge the complete 
spinal cord lesion. A partial restoration of hind limb function in rats was achieved 
(Cheng et al. 1996). Since then, many further attempts have been made by using 
peripheral nerve grafts combined with neurotrophic factors and/or chondroitinase to 
repair the injured spinal cord. Axonal regeneration and functional recovery has been 
shown (Cote et al. 2011). Further improvement of the surgical technique and 
introduction of a biodegradable device to hold the peripheral nerve grafts and to direct 
the regenerating axons to the grey matter, has resulted in improved functional recovery 
and motor evoked potentials (Nordblom et al. 2012; Nordblom et al. 2009). 
 
Schwann cells form the myelin sheaths around the peripheral nerves. They are able to 
remyelinate the injured axons, promote axonal regeneration by release of growth 
factors and other growth promoting substances such as laminin and fibronectin 
(Bozyczko and Horwitz 1986; Cornbrooks et al. 1983; Oudega and Xu 2006; 
Wiliams and Bunge 2012). Grafted Schwann cells are also thought to recruit 
endogenous host Schwann cells into the injured spinal cord (Biernaskie et al. 2007; 
Hill et al. 2006). However, Schwann cells alone seemed not to promote outgrowing 
axons to overcome the inhibiting glial scar, and hence combination strategies are 
needed to yield better results (Bunge 2008; Oudega and Xu 2006; Pearse et al. 2007). 
A recent clinical study in eight patients with complete (American Spinal Injury 
Association Impairment scale A (ASIA-A)) chronic SCI in Iran evaluated the safety 
and outcome of autologous transplantation of Schwann cells and BMSCs. No adverse 
observations were reported in any of the enrolled patients up to 2 years following 
transplantation (Yazdani et al. 2013). 
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In rats, recovery of hind limb function has been reported after transplantation of 
activated macrophages. The macrophages were activated by incubation with skin 
tissue or peripheral nerve segments (Bomstein et al. 2003; Rapalino et al. 1998). 
Activation of intrinsic macrophages in the injured spinal cord by IL-12 was also 
reported to benefit a functional recovery in a mice model (Yaguchi et al. 2008). It has 
been suggested that activated macrophages might be a therapeutic target for SCI. In a 
non-randomized Phase I study performed in Israel, ASIA-A patients with SCI in C5-
T11 were given activated autologous macrophages into the spinal parenchyma at the 
border of the lesion within 14 days after injury. The results showed that the cell 
therapy was well tolerated in patients (Knoller et al. 2005). However, a recent phase 
II randomized controlled multicenter trial reported that transplantation of activated 
autologous macrophages into ASIA-A to C patients with acute complete C5-T11 
injuries failed to show an improved functional outcome (Lammertse et al. 2012). 
 
OECs are glial cells found in the nerve fiber layer in the olfactory bulb, in the nasal 
olfactory mucosa and surrounding the cranial olfactory nerve fibers, with the property 
to grow throughout life (Graziadei and Graziadei 1979). OECs are relatively easy to 
obtain from nasal biopsies and could provide an autologous cell source for grafts. 
Transplantation of OECs into the injured spinal cord has resulted in increased axonal 
growth, modulation of the inflammatory response and better functional recovery after 
SCI (Kubasak et al. 2008; Munoz-Quiles et al. 2009; Ramon-Cueto 2011). However, 
the ability of OECs to migrate and to guide re-growing axons appears to be limited by 
scar tissue (Deng et al. 2006; Lee et al. 2004). In addition, it is unclear whether OECs 
can be expanded to sufficient numbers for the purpose of cell therapy. Clinical trials 
have proved the safety of OECs transplantation in SCI (Feron et al. 2005; Lima et al. 
2006), however, the efficiency of the treatment was not encouraging (Radtke et al. 
2008). 
 
The most common non-neural cell type applied in experimental or clinical SCI 
transplantation therapies is BMSCs. The BMSCs are easy to access for autologous 
transplantation and have relatively well-known immunomodulatory properties. 
BMSCs have been suggested to provide support for axonal regeneration and improve 
functional recovery following experimental SCI (Ankeny et al. 2004; Chopp et al. 
2000; Ide et al. 2010; Neuhuber et al. 2005; Ohta et al. 2004; Zurita and Vaquero 
2004). Better results were achieved with BMSC injections one week after injury than 
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immediately after injury (Hofstetter et al. 2002). A number of completed and ongoing 
clinical trials involving transplantation of BMSCs in SCI have reported the feasibility 
of this treatment, while the functional outcomes vary from different studies (Mothe 
and Tator 2012). However, in addition to these beneficial effects, there are recently 
reported adverse effects of BMSCs, such as enhanced tumor growth and metastases 
(Ramasamy et al. 2007; Zhang et al. 2013). Thus, further and more careful and 
detailed studies on clinical safety and efficacy of BMSCs should be performed. 
 
Human pluripotent ESCs have the ability to proliferate for a long period under in 
vitro conditions and have the potential to differentiate into any cell types of the three 
germ layers, including specific cells of neuronal or glial fates. This enables them to 
give rise to potential neural cells for application in SCI. Pre-differentiated ESCs 
transplanted into the injured spinal cord survived, differentiated into neurons and glial 
cells and showed partial functional recovery (Keirstead et al. 2005; McDonald et al. 
1999; Nistor et al. 2005; Sharp et al. 2010). However, the application of ESCs has 
been limited due to the difficulty of generating high-purity lineage-specific cell lines 
without risk of tumorgenesis and without ethical issues. The generation of iPSCs 
provides an alternative therapeutic approach for cell therapy in SCI. The use of 
autologous iPSCs derived from the patient’s own somatic cells represents a cell 
source which is ethically acceptable for most stake-holders, and may mitigate the 
need for immunesuppression. Transplantation of iPSC derivates into the injured 
rodent spinal cord showed improvement of locomotor recovery with synapse 
formation, axon regeneration, increased remyelination and angiogenesis (Fujimoto et 
al. 2012; Nori et al. 2011; Tsuji et al. 2010). However, iPSC differentiation to neural 
lineages may occur at a much lower frequency than ESCs (Hu et al. 2010). Some 
types of iPSC-derived neural cells also involve the risk of tumor formation after 
transplantation. Thus, it is still a big challenge to produce safe iPSC-derived neural 
cells for transplantation. 
 
NPCs are multipotent cells committed to the neural lineage that can self-renew and be 
readily expanded in vitro. NPCs are of particular interest for SCI repair. NPCs, 
derived from adult and fetal central nervous system (CNS) tissues, as well as from 
ESCs and iPSCs as mentioned above, have been reported to survive, differentiate into 
neurons and glial cells and to improve functional recovery after transplantation in SCI 
animal models (Amemori et al. 2013; Fujimoto et al. 2012; Sandner et al. 2012; 
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Tetzlaff et al. 2011; van Gorp et al. 2013). The mechanism(s) behind the 
improvement in grafted NPCs is only now beginning to be understood, and several 
potential mechanisms have been suggested (see details in section 1.4). Adult NPCs 
have been reported to present limited replication potential (Doetsch et al. 1999; 
Morshead et al. 1998) and decreased differentiation potential with time in culture 
(Wright et al. 2006), which would limit clinical application. In addition, the ethical 
and practical challenges and concerns imposed by the NPC origins and derivation 
should not be ignored. Nevertheless, a part of the scientific community still believes 
that NPCs represent an ideal candidate for cell-based treatment of SCI due to 
functional improvement noticed after transplantation. Finally, NPC populations 
deriving from the already formed nervous system have not been reported to cause 
tumor formation with metastasis after transplantation, which is an important criteria 
for a donor cell population in cell therapy. 
 
Despite all the strategies described above with a promising therapeutic potential in 
experimental SCI, very few translational studies have resulted in functional 
improvement in the clinic. Therefore it is important and necessary to continue the 
search for and development of potent SCI treatments. 
 
1.4 Potential therapeutic effects of transplanted neural cells 
Extensive studies have reported the structural and functional restoration from 
transplantation of neural cells in SCI (Donnelly et al. 2012; Nakamura and Okano 
2013; Ruff et al. 2012; Sandner et al. 2012; Tetzlaff et al. 2011). Neural cell 
therapies, contrary to single-molecule-based pharmalogical interventions, hold the 
potential to deliver a complex series of factors and signals to a multitude of targets in 
the diseased microenvironment. 
 
Cell replacement 
After SCI, a significant loss of neural cells occurs and contributes to the functional 
deficits (Dumont et al. 2001). Thus, replacement of lost or damaged neurons is an 
important goal in neural cell transplantation. A key prerequisite for neuronal 
replacement is that grafted stem/progenitor cells differentiate into appropriate neural 
cells. Transplanted NPCs have been shown to differentiate into neurons (Cummings 
et al. 2006; Cummings et al. 2005; Ogawa et al. 2002; Yan et al. 2007), 
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oligodendrocytes (Karimi-Abdolrezaee et al. 2006; Setoguchi et al. 2004) and 
astrocytes (Cao et al. 2001), and result in improved function outcome. 
 
Remyelination 
The loss of oligodendrocytes at and around the lesion site, the resulting wide spread 
demyelination and the loss of appropriate nerve conduction significantly contribute to 
functional deficits after SCI (Hulsebosch 2002). Regenerative strategies aimed at 
remyelination represent a promising way to functional restoration after SCI. Pre-
differentiated oligodendrocyte progenitor cells (OPCs) or mature oligodendrocytes 
from ESCs were reported to remyelinate spared axons and improve locomotor 
function, when transplanted into the injured spinal cord (Keirstead et al. 2005; Nistor 
et al. 2005; Sharp et al. 2010). Another study also described the restoration of motor-
evoked potentials and compound motor action potentials that resulted from the 
remyelination after NPC transplantation into the contused spinal cord (Yasuda et al. 
2011). Transplanted human NPCs were also reported to support axon remyelination 
(Xu and Onifer 2009). 
 
Axonal regeneration 
The failure of injured axons in the CNS to regenerate leads to permanent paralysis 
and other functional deficits after SCI. Numerous studies have examined 
transplantation of different cell types to create a permissive environment for axon 
regeneration. Spinal cord-derived NPCs (SC-NPCs) grafted into the transected rat 
cervical dorsal column elicited enhanced re-growth of corticospinal axons for a 
limited distance into the graft. Co-localization of regenerating axons with graft- 
derived GFAP-expressing astrocytes suggested that NPC-derived astrocytes can 
provide a cellular scaffold for injured axons (Pfeifer et al. 2004). Similar mechanisms 
have been described when glial restricted precursor (GRP)-derived astrocytes were 
grafted into the injured rat spinal cord, resulting in a superior locomotor recovery 
determined by grid-walk analysis (Davies et al. 2006). The lesion site contains 
multiple inhibitors of axon outgrowth, such as CSPGs and myelin derived inhibitors 
as described above (see section 1.2). Hill and colleagues impressively showed that 
acutely transplanted GRPs both decreased astrocytic scarring and proteoglycan 
deposition 8 days after contusion resulting in an increased number of corticospinal 
tract axons (Hill et al. 2004). 
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Synaptic formation 
In addition to axonal regeneration, another important regenerative strategy for SCI is 
to promote synaptic formation and connection. Bonner et al. grafted a mix of GRPs 
and neuronal progenitors into the injured dorsal column, and observed that the donor 
progenitors formed a neuronal relay by extending active axons across the SCI to the 
intended target. Furthermore, synaptic connections between regenerating host axons 
and graft-derived neurons were established (Bonner et al. 2011). Two additional 
studies also reported that NPC-derived neurons formed new synaptic contacts with 
host cells after SCI followed by significant functional recovery (Lai et al. 2013; Lu et 
al. 2012). 
 
Stimulation of endogenous repair 
After SCI, endogenous NPCs, located in the white matter parenchyma or close to the 
central canal of the spinal cord, are responsive to injury (Obermair et al. 2008). 
Endogenous NPCs were reported to proliferate and differentiate into mature 
remyelinating oligodendrocytes and/or astrocytes (Ke et al. 2006; Obermair et al. 
2008). However, endogenous NPCs did not lead to complete recovery in cases of 
severe trauma due to the limited proliferation and differentiation capacity. In 
experimental autoimmune encephalomyelitis (EAE), an animal model of multiple 
sclerosis, Einstein et al. demonstrated that grafted NPCs stimulated resident OPC 
proliferation and enhanced remyelination (Einstein et al. 2009). Recently, it was also 
reported that transplanted NPCs increased the neurogenesis from endogenous NPCs 
in the subgranular zone of dentate gyrus (Jin et al. 2011) and subventricular zone in 
the brain (Mine et al. 2013).	  
 
Neuroprotection 
Since secondary degenerative processes after experimental SCI proceed for at least a 
few weeks in rats, an important mechanism is a neuroprotective effect by neural cell 
therapy in the acute and subacute stage to rescue vulnerable neural cells. In later 
stages, transplanted cells may provide trophic support to promote survival of host 
cells at the lesion site, and/or supply the injured tissue with an extracellular matrix 
that is more permissive to regeneration. Lu et al. showed that, when grafted to cystic 
dorsal column lesions in the cervical spinal cord of adult rats, NPCs produced 
neurotrophic factors and protected host axons (Lu et al. 2003). Similarly, it was 
reported that NPCs protected motor neurons against excitotoxicity in spinal cord 
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organotypic cultures via release of trophic factors (Llado et al. 2004). NPCs may also 
interfere with the production of free radicals by the release of neuroprotective factors 
and therefore regulate the oxidative stress occurring after SCI (Madhavan et al. 
2008). 
 
Immunomodulation 
Inflammation characterized by infiltration of peripheral immune cells and activation 
of microglia play an important role in the pathophysiological development of SCI as 
described above. In EAE, NPCs were reported to inhibit T-cell proliferation and 
promote apoptosis of encephalitogenic CNS-infiltrating T cells through apoptotic 
receptor ligands (e.g. FasL, Apo3L) and release of soluble mediators (e.g. NOS, 
leukemia inhibitor factor) in the chronic inflammatory environment (Einstein et al. 
2007; Einstein et al. 2006; Pluchino et al. 2005). Reduction of the microglial/ 
macrophage response was observed in stroke after NPC allotransplantation in rodent 
models, with improved locomotor functions (Bacigaluppi et al. 2009; Lee et al. 
2008). Furthermore, subacute transplantation of NPCs in a stroke model led to 
significant down-regulation of inflammation-related genes, including IFN-γ, TNF-α, 
IL-1β, IL-6 and leptin receptor (Bacigaluppi et al. 2009). However, relatively few 
studies have been conducted that concern the anti-inflammatory and 
immunomodulatory effects of NPCs in SCI and in particular human donor NPCs. 
Grafted mouse NPCs in SCI mice were reported to migrate to the injury site and 
synergistically promote functional recovery via modulation of the nature and intensity 
of the local T cell and microglial response (Ziv et al. 2006). Cusimano and co-
workers found that subacutely transplanted mouse NPCs reduced the proportion of 
“classically-activated” M1 macrophages and increased that of regulatory T cells 
(Tregs), in turn promoting repair of the injured spinal cord (Cusimano et al. 2012). 
Grafted human ESC-OPCs in the EAE mice were able to induce the infiltration of 
TREM2+ CD45 cells, which are specific for tissue regeneration and clearing of cell 
debris (Kim et al. 2012a). Transplanted human GRPs were also shown to ameliorate 
EAE paralysis by inhibiting T cell proliferation and the activation of macrophages 
and/or microglia in the brain (Kim et al. 2012b). 
 
1.5 Immunogenicity of NPCs and their interactions with immune cells 
The immunogenicity of a donor cell population is describing its ability to elicit a host 
immune response after transplantation. Transplantations can be categorized depending 
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on donor and host cell or tissue origin. A xenogeneic transplantation is the 
transplantation of living cells, tissues or organs to a recipient from another species than 
the donor. Allogeneic transplantation is the transfer of cells, tissues or organs to a 
genetically non-identical recipient from the same species as the donor. A syngeneic 
transplantation is cell or tissue transfer between genetically identical individuals, while 
in an autologous transplantation, donor and host is the same individual. 
 
A rejection response to allogeneic cells is the result of interactions involving 
coordination between both the innate and adaptive immune system with T cells playing 
a central role. A rejection is initiated by recognition of antigens on donor cells by T 
cells via the direct pathway to recognize intact non-self MHC molecules present on the 
cell surface, or by the indirect pathway including the presentation of processed donor 
MHC molecules presented as peptides by self-MHC molecules (Ingulli 2010). 
Xenograft responses differ from alloresponse by comprising hyperacute and delayed 
rejection. Hyperacute rejection is mediated by xenoreactive natural antibodies and 
activation of the recipient’s complement system. Delayed xenograft rejection is caused 
by natural antibodies and cellular xenograft rejection involving either T cells or cells 
from the innate immune system, or both (Yang and Sykes 2007). The rejection of 
cellular xenografts is stronger than an allorejection (Buhler and Cooper 2005). 
 
The presence of human leukocyte antigen (HLA) class I and II molecules (Johansson et 
al. 2008; Laguna Goya et al. 2011; Odeberg et al. 2005; Ubiali et al. 2007) in 
conjunction with co-stimulatory molecules CD40, CD80 and CD86 (Odeberg et al. 
2005) on human NPCs implies a risk for recognition and rejection by non-compatible 
alloreactive immune cells after transplantation. Varying results have been reported in 
studies analyzing allogeneic T-cell proliferation stimulated by human NPCs and their 
derivates from different origins in in vitro assay. Previous study showed that human 
NPCs derived from first trimester nervous system (hfNPCs) did not trigger an 
allogeneic lymphocyte response (Odeberg et al. 2005). Similar findings on human 
ESC-derived oligodendrocytes were reported by Okamura et al. (Okamura et al. 2007). 
In contrast, human NPCs derived from ESCs (hESC-NPCs) or fetal forebrain elicited 
significant T cell proliferation (Preynat-Seauve et al. 2009; Ubiali et al. 2007). The 
possibility to derive human neural cells from iPSCs (Chambers et al. 2009; 
Karumbayaram et al. 2009; Takahashi and Yamanaka 2006) or by direct induction of 
non-neural differentiated cells to neural cells (Vierbuchen et al. 2010) offers autologous 
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cell therapy with reduced ethical concerns and lessened risk of rejection. However, 
even grafted iPSCs can induce a T-cell-dependent immune response in syngeneic 
recipients (Zhao et al. 2011). Irrespective of their origin, in vitro modified and 
expanded donor cells may present changes in cellular characteristics and protein pattern, 
putting them at risk of being rejected. 
 
The interaction between neural and immune cells is complex. Xenografted human 
NPCs from different origins were partly or fully rejected with or without 
immunosuppression (Hovakimyan et al. 2012; Jablonska et al. 2013; Wennersten et al. 
2006). Allogeneic NPCs transplanted into the injured rat spinal cord were subjected to 
chronic host rejection, though long-term survival of grafted NPCs was still observed 
(Xu et al. 2010). In contrast to triggering immune responses, grafted NPCs may also 
interact with immune cells to counteract a deleterious inflammatory environment in 
rodent neurological disease models (Bacigaluppi et al. 2009; Cusimano et al. 2012; 
Daadi et al. 2010; Einstein et al. 2007; Lee et al. 2008). However, it is not fully 
understood how these still immature neural cells exert their immunomodulatory effects 
and whether similar immunomodulation can take place in an allogeneic human 
situation. 
 
Grafted mouse NPCs in an EAE model protected against chronic host neural tissue 
loss as well as disease-related disability by inducing apoptosis of blood-born CNS-
infiltrating encephalitogenic T cells (Pluchino et al. 2005). It was further shown that 
NPCs selectively increased the apoptosis of pro-inflammatory T helper 1 (Th1) and 
Th17 (but not anti-inflammatory Th2) cells in vitro through the apoptotic receptors 
FasL, TRAIL and Apo3L (Knight et al. 2011; Pluchino et al. 2005). Rodent NPCs 
inhibited allogeneic T cell activation and proliferation in response to T cell receptor-
mediated stimuli (Einstein et al. 2003; Fainstein et al. 2008), and the inhibitory effect 
of NPCs may partly depend on the inhibition of IL-2 and IL-6 signaling on T cells 
(Fainstein et al. 2008), the production of heme oxygenase-1 (Bonnamain et al. 2012), 
nitric oxide and prostaglandin E2 (Wang et al. 2009). A recent study described that 
mouse NPCs were able to selectively inhibit pathogenic Th17 cell differentiation by 
the production of leukemia inhibitor factor, which antagonized IL-6-induced Th17 
cell differentiation through the extracellular signal-regulated MAP kinase-dependent 
inhibition of signal transducer and activator of transcription-3 phosphorylation (Cao 
et al. 2011). Human NPCs suppressed the proliferation of non-human primate or 
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rodent activated T cells in vitro or in EAE model through both direct cell-to-cell 
contacts and via the release of soluble mediators such as TGF-β (Kim et al. 2009; 
Pluchino et al. 2009a; Ubiali et al. 2007). In addition, NPCs were reported to restrain 
the maturation of myeloid dendrite cells via a bone morphogenetic protein-4-
dependent mechanism in both ex vivo and in vitro experiments (Pluchino et al. 
2009b). Allogeneic hESC-NPCs in an in vitro study also induced a strong natural 
killer cells cytotoxic response, which was driven by activating NKG2D receptor 
(Preynat-Seauve et al. 2009). 
 
Cusimano et al. showed that transplanted mouse NPCs interacted with host 
macrophages via connexin43+ cellular junction and reduced the proportion of M1 
macrophages, leading to a reprogramming of the local inflammatory cell 
microenvironment from a “hostile” to an “instructive” state, thus promoting the repair 
of the injured spinal cord (Cusimano et al. 2012). Mosher et al. reported that both 
mouse and rat NPCs regulated microglial functions and activity at least partly through 
the production of vascular endothelial growth factor by NPCs (Mosher et al. 2012). 
Recently, Cusulin et al. showed that mouse ESC-NPCs could fuse with rodent 
microglia with retained genetic and functional characteristics, at least partly through 
interaction between phosphatidylserine exposed on the NPCs and the CD36 receptor on 
microglia (Cusulin et al. 2012). However, the interplay of human NPCs and microglial 
cells still to a large degree is unclear. 
 
As mentioned above, donor NPCs are able to interact with immune cells, even exert 
immunomodulation on the grafted hosts. However, it needs to be noticed that, most 
current studies graft human NPCs into genetically immunodeficient animals to 
investigate the cellular basis of functional recovery without having a rejection 
response. Thereby, the question, how the intact immune system will interfere with 
human NPCs short and long term, remains unanswered. Discovery of biological and 
clinical signs of ongoing rejection in patients with Huntington’s disease following 
allogeneic fetal neural grafts (Krystkowiak et al. 2007) underlined the importance of 
considering immune responses in the CNS as a crucial parameter for cell 
transplantation strategies. In other studies, immunocompetent rodents are employed 
followed by immunosuppression to prevent cellular rejection after transplantation of 
human donor cells, which leads to other issues, such as the differences between 
xenograft response and allorecognition as mentioned above. Clinical trials including 
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neural transplantation in Parkinson’s disease and SCI patients have also reported 
survival of allografted human donor tissues despite withdrawal of immunosuppressive 
treatments (Falci et al. 1997; Piccini et al. 2005). However, in the allograft trial in 
Huntington’s disease patients mentioned above, a delayed rejection response was 
observed (Krystkowiak et al. 2007). The failure of clinical trials may in part be due to 
the underestimation of the complexity of the interaction of the human nervous and 
immune system, as well as the type and duration of immunosuppressant used. 
Therefore, preclinical studies, with experimental models that are more close to the 
clinical situations, are needed to bring up more reliable and strong preclinical 
evidence. 
 
For successful clinical neural cell transplantation, we need to expand our knowledge 
on how immune cells influence the function of donor NPCs and their progeny in the 
host tissue. Allogeneic transplantation of ESC-NPCs into intact mouse brain causes 
the accumulation of host microglia/macrophages and lymphocytes around the graft, 
which suppressed neuronal differentiation of grafted NPCs by producing cytokines 
such as IL-6 (Ideguchi et al. 2008). In coherence, Gomi and colleagues showed 
similar phenomenon after allogeneic ESC-NPCs implantation, and further 
demonstrated that blockade of the accumulation of CD8+ T cells, as well as reduction 
of the levels of IL-6, resulted in an increased percentage of neurons (Gomi et al. 
2011). Finally, in vitro studies have also indicated that the microglia activation states 
could differently affect NPCs (Butovsky et al. 2006; Cacci et al. 2008; Gu et al. 
2011). 
 
1.6 Human neural cell therapy in SCI clinical trials 
Multiple clinical trials including allogeneic human neural cell or solid tissue 
transplantation therapy have been performed up to date (see section 1.2). Here three 
important studies including in vitro expanded human donor neural cells will be 
described. 
 
Based on promising preclinical data of human ESC-OPCs in rodent SCI models 
(Keirstead et al. 2005; Sharp et al. 2010), the US Food and Drug Administration 
approved the first human ESCs trial in 2009. A phase I multicenter trial was performed 
by Geron Corp. (clinicaltrials.gov identifier: NCT01217008) starting in 2010. Patients 
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with complete thoracic SCI (ASIA-A) were injected with 2 million human ESC-OPCs 
(GRNOPC1) into the spinal cord lesion site subacutely (between 7-14 days after 
injury). The enrolled patients will be followed for 15 years after transplantation. 
However, Geron has discontinued the trial after five patients having received 
GRNOPC1 therapy and 45-60 days of immunosuppression with tacrolimus (Prograf). 
No safety issues were reported in any of the grafted patients, but complete results 
have not been published. 
 
Preclinical studies of human fetal brain-derived NPCs, that differentiated into 
myelinating oligodendrocytes and synapse-forming neurons as potential mediators of 
functional recovery in experimental SCI models (Cummings et al. 2005; Hooshmand et 
al. 2009; Salazar et al. 2010), provided the foundation for a phase I/II clinical trial 
started by StemCells Inc. (clinicaltrials.gov identifier: NCT01321333) in Switzerland 
from 2011. The trial is designed to assess the safety and preliminary efficacy in 12 
patients with thoracic SCI with variable degrees of paralysis (ASIA A-C), 3–12 months 
post-injury. Patients receive human CNS-derived NPCs (HuCNS-SC) directly into the 
injury site and are given 9 months of immunosuppressive drugs, following a 12-month 
period to monitor safety and potential changes in sensation, motor and bowel/bladder 
function. Up till now, three ASIA A patients have been enrolled with no complications 
or side effects reported. Signs of segmental improvement have been observed in two 
out of the three patients (Guzman et al. 2013). 
 
Another phase I multicenter trial using human spinal cord-derived neural stem cells 
(HSSC) has been proposed and sponsored by Neuralstem Inc. (clinicaltrials.gov 
identifier: NCT01772810) in USA since Jan. 2013. The trial is designed to evaluate the 
safety and the graft survival in eight patients with complete thoracic SCI (ASIA-A) at 
T2-12. Patients will be divided into two groups and receive different amount of HSSC 
at 1-2 years post-injury, and 3 months of immunosuppression with tacrolimus (Prograf) 
and mycophenolate mofetil (CellCept). A total of 60 months of observation will be 
conducted after transplantation. No patient has been recruited to date 
(http://www.neuralstem.com/cell-therapy-for-sci). 
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2 AIMS OF THE THESIS 
The overall aim was to understand the host response and interactions between host and 
donor cells in human neural cell therapy after SCI. 
 
The specific aims of this thesis work were: 
 To characterize the immunocompetence and immunogenicity of human NPCs 
and their interaction with allogeneic peripheral blood mononuclear cells 
 To determine the nature of the interaction between human NPCs and allogeneic 
microglia 
 To understand allogeneic and xenogeneic host responses to human neural cell 
therapy in in vitro and in vivo models of SCI 
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3 MATERIALS AND METHODS 
3.1 Cell and tissue cultures (Paper I-IV) 
3.1.1 Human ESC culture (Paper I) 
Human ESCs were derived from the inner cell mass of 5/6-day-old pre-implantation 
blastocyst-stage embryos obtained after in vitro fertilization. The embryos used in this 
thesis had been disqualified from infertility treatment and was donated for human ESC 
derivation after informed consent from the couple. The Regional Ethics Committee, 
Stockholm, Sweden has given approval for the derivation, expansion, and 
differentiation of hESC lines. Human ESCs were initially derived and cultured using 
postnatal human foreskin fibroblasts (CRL-2429, ATCC) as feeder cells and serum 
replacement medium as previously described (Inzunza et al. 2005), then the colonies 
were passaged by mechanical splitting at 5- to 7-day intervals and replated on γ-
irradiated (35Gy) fibroblasts. The cell culture medium was changed once per day. 
 
Later, suspension cultures were set up for human ESCs to reduce the risk of feeder cell 
contamination, by applying the protocol developed by (Steiner et al. 2010). Briefly, 
human ESC colonies were mechanically split and transferred to Neurobasal medium 
containing 14% knockout serum replacement, 2mM GlutaMax, 50U/ml penicillin/ 
streptomycin, and 1% non-essential amino acids (all from Life Technologies), 
supplemented with 20ng/ml human basic FGF (R&D), 25ng/ml activin A, BDNF, NT-
3 and NT-4, 10ng/ml each (all from Peprotech), 1µg/ml fibronectin (BD Biosciences), 
0.5µg/ml laminin, 0.001% gelatin (both from Sigma) and 1×Nutridoma-CS (Roche). 
After 6–7 days, the colonies formed spheres and the spheres were thereafter 
mechanically split every 7–10 days. The medium was changed every other day. Human 
ESC spheres between passage 4 and 10 were used in this thesis. 
 
3.1.2 Neural induction of human ESCs (Paper I) 
The neural induction was performed with human ESC spheres according to the protocol 
by Chambers et al. (2009). Briefly, the initial differentiation medium consisted of 
human ESC-medium with 10µM TGF-β inhibitor SB431542 (Tocris) and 500ng/ml 
Noggin (R&D). Upon day 5 of differentiation, increasing amount of N2 medium (25%, 
50% and 75%) was added to the human ESC-medium every two days while 
maintaining 10µM SB431542 and 500ng/ml Noggin. After 8 days, the spheres were 
cultured in NPC medium (DMEM/F12, 0.6% glucose, 5mM Hepes, 2µg/ml Heparin 
and 1% N2 supplement, all from Life Technologies) supplemented with 20ng/ml 
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human epidermal growth factor and 20ng/ml human basic FGF (both from R&D) and 
mechanically passaged once per week up to 20 weeks after neural induction. All 
cultures were maintained in a humidified atmosphere at 37°C and 5% CO2. The 
medium was changed every other day. The hESC-NPCs between passage 12-16 were 
used in this thesis. 
 
3.1.3 hfNPC culture (Paper I-IV) 
Cultures of hfNPCs derived from two regions of human first trimester CNS (5-7.5 
weeks of gestation) were used in this thesis: SC-NPCs from the spinal cord, and FBr-
NPCs from the sub-cortical forebrain. The procedure was approved by the Regional 
Ethics Committee, Stockholm, Sweden. Briefly, tissue was retrieved from clinical first 
trimester routine abortions after informed consent by women undergoing termination of 
pregnancy. Identified tissue was homogenized and cultured at 100,000-200,000 
cells/ml in NPC medium supplemented with 20ng/ml human epidermal growth factor, 
20ng/ml human basic FGF and 10ng/ml ciliary neurotrophic factor (all from R&D) as 
described previously (Akesson et al. 2009). The free-floating neurospheres were 
passaged every 7–14 days by enzymatic dissociation using TrypLE Express (Life 
Technologies) with fresh medium added twice a week. All cultures were maintained in 
a humidified atmosphere at 37°C and 5% CO2. hfNPCs between passage 0-10 were 
used in this thesis. 
 
3.1.4 IFN-γ and/or TNF-α stimulation of human NPCs (Paper I) 
Human NPCs were stimulated in vitro with 200U/ml IFN-γ (R&D), 10ng/ml TNF-α 
(R&D) or a mixture of both for three days, with the removal of ciliary neurotrophic 
factor from the culture medium of hfNPCs. Thereafter, neurospheres were dissociated 
into single-cell suspension for flow cytometric analysis or for co-culture with 
peripheral blood mononuclear cells (PBMCs), and the supernatant was collected for 
cytokine analysis. 
 
3.1.5 Human microglial culture (Paper II) 
The human microglia line CHME3 was obtained as a kind gift from Professor M. 
Tardieu (Neurologie pédiatrique, Hôpital Bicêtre, Assistance publique, Hôpitaux de 
Paris, Paris, France), and cultured as described previously (Hjorth et al. 2010). Briefly, 
CHME3 microglial cells (hereafter called microglia) were cultured in DMEM/high 
glucose without sodium pyruvate supplemented with 2mM GlutaMaxII and 10% heat-
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inactivated fetal bovine serum (all from Life Technologies) at 37°C and 5% CO2. 
Microglia were subcultured at confluence using enzyme-free cell dissociation buffer 
(Life Technologies). 
 
3.1.6 Human fibroblast culture (Paper II) 
Human foreskin fibroblasts (hereafter called fibroblasts) were cultured in Iscovs 
DMEM medium supplemented with 10% fetal bovine serum (all from Life 
Technologies) to form a confluent monolayer 37°C and 5% CO2. The cells were 
enzymatically passaged once per week using TrypLE Express (Life Technologies). 
 
3.1.7 Co-culture of hfNPCs and microglia (Paper II) 
The hfNPCs were differentiated at a concentration of 10,000 cells/cm2 in poly-D-lysine 
(0.1mg/ml) and fibronectin (0.1mg/ml, both from Sigma) coated plates or flasks and 
NPC medium supplemented with 1% fetal bovine serum (without mitogens present) for 
4 days, to achieve a NPC population just entering differentiation. To mimic an 
encounter of naïve host microglial cells with donor hfNPCs, unstimulated microglia 
were added directly to the cultures of differentiating hfNPCs on day 4, allowing cell-
cell contact at a concentration of 10,000 cells/cm2 and the medium volume of 
0.1ml/cm2. Co-cultures were kept in DMEM/F12 and 1% fetal bovine serum for 24 h to 
allow microglia to attach. Thereafter, hfNPCs and microglia were co-cultured in serum-
free medium for up to 48h to avoid the interference of serum to the subsequent cytokine 
analysis. hfNPC and microglial mono-cultures were processed as controls. hfNPCs co-
cultured, under equivalent conditions in sequence as above, with equal amount of 
fibroblasts or hfNPCs were also set up as controls for some experiments. On day 7, the 
cells were harvested for further analysis. 
 
3.1.8 Mixed lymphocyte cultures (MLC) (Paper I, III) 
In Paper I, human adult PBMCs were prepared by centrifuging peripheral blood on a 
Ficoll gradient (Lymphoprep, Nycomed Pharma) at 500g without brakes for 20 minutes 
at room temperature. Human CD4 and CD8 T cells were sorted and purified using anti-
human CD3, CD4 and CD8 antibodies by FACSAria™ III (Becton and Dickinson). In 
Paper III, rats PBMCs were isolated at 6-week end point from whole blood using 
NycoPrep (Axis-shield) according to manufacturer’s instructions. Spleenocytes were 
isolated by homogenizing tissue, washed in phosphate-buffered saline, counted and 
resuspended. 
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One hundred thousand PBMCs (responder PBMCs) or T cells from one donor were co-
cultured with 100,000 irradiated (20Gy) stimulator PBMCs or T cells from one or five 
donors. Triplicate samples were cultured in 0.2ml RPMI medium (RPMI 1640 medium 
supplemented with 100U/ml penicillin, 100mg/ml streptomycin, 2mM L-glutamine and 
5% pooled normal human male AB serum, all from Life Technologies) per well in 96-
well plates. The cell death, differentiation and expression of HLA and co-stimulatory 
molecules by human NPCs after 6 days in RPMI medium were analyzed by flow 
cytometry. 
 
To study the effect of human NPCs on PBMC or T cell proliferation, in Paper I, 
10,000 or 100,000 irradiated hESC-NPCs or hfNPCs (human NPCs: responder 
PBMC/T cells = 1:10 or 1:1 ratio) were co-cultured for 6 days at 37°C and 5% CO2. 
Neutralizing monoclonal antibody to TGF-β1 (clone 9016, 10ng/ml, R&D) was added 
to study the effect of TGF-β1 in MLC. In Paper III, 50,000 rat PBMCs from moderate 
SCI groups were co-cultured with 500,000 irradiated (20Gy) hfNPCs. On day 5, 1 
mCi/ml of [3H]thymidine was added and the cells were harvested after 24 hours. 
[3H]thymidine DNA incorporation was evaluated using a semiautomatic harvesting 
machine (Harvester 96, Tomec) and presented as counts per minute (Paper I) or 
stimulation index (Paper III). [3H]thymidine incorporation in PBMCs or T cells co-
cultured with equal amount of irradiated autologous PBMCs or T cells served as 
negative controls, and the thymidine incorporation in PBMCs co-cultured with equal 
amount of irradiated allogeneic pool PBMCs from five donors served as positive 
controls. Values below three times the background are considered as negative. 
 
3.1.9 Human organotypic slice cultures (Paper III, IV) 
Fresh human spinal cord tissues were sliced at 200µm of thickness. Slices were 
cultured on a semi-porous membrane (pore size 0.4µm, Millipore-Merck) pre-treated 
with poly-D-Lysine (Life Technologies) and in 1.2ml culture medium (DMEM/F12 
with Glutamax, 25% inactivated horse serum, 36mM glucose, 15mM Hepes and 
25U/ml penicillin/ streptomycin, all from Life Technologies). Tissues were maintained 
at 37°C, 5%CO2, 95% humidity, and the medium was changed twice a week. 
 
At 7 days in culture, contusion injury was achieved on slices using the Infinite Horizon 
impactor (25kdyn force). One 250–350µm spinal cord-derived neurosphere or a sham 
injection was applied to the surface of the organotypic slice one hour after injury. The 
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experimental groups were: 1) Sham; 2) Sham+SC-NPCs; 3) SCI; 4) SCI+SC-NPCs. 
Slice cultures at 7 and 14 days post-injury with or without SC-NPCs were dissociated 
into single-cell suspensions for flow cytometric analysis. 
 
3.2 Experimental animals (Paper III, IV) 
Female Harland Sprague Dawley rats (B-land, Denmark, Paper III) and adult 
immunodeficient athymic female rats (Hsd: RH-rnu/rnu, Harlan, Paper IV) were used 
in this thesis. The experimental animals were housed in an isolated environment of 
enriched cages with a 12-hour ligh-dark cycle and access to autoclaved water and food 
pellets ad libitum. All experimental procedures were carried out in accordancec with 
the guidelines provided by The Swedish National Board and NIH for Laboratory 
animals, and the experimental procedures were approved by the Regional Ethics 
Committee on Animal Research, Stockholm, Sweden.  
 
3.3 Surgical and transplantation procedures (Paper III, IV) 
The experimental rats (170–200g) were injected intraperitoneally with 0.05mg/kg 
Atropin (NM Pharma AB) 30 minutes before surgery, and anesthetized using Hypnorm 
(0.22mg/kg fentanyl citrate and 6.8mg/kg fluanisome, Janssen Pharmaceutical) and 
3.4mg/kg midazolam (Hoffman-La Roche). Body temperature was kept at 38°C 
throughout surgery. Lumbar spinal cords were surgically exposed by partial 
laminectomy of vertebra T13 with a few drops of 20mg/ml lidocain hydrocloride 
(AstraZeneca) on the exposed spinal cord surface. Spinal cord contusion injury was 
achieved with an IH spinal cord impactor (Precision Systems and Instrumentation, 
LLC), the force set to 150kdyn, 200kdyn (Paper III) and 175kdyn (Paper IV) with no 
dwell time. For lateral compression injuries (Paper IV), a modification of the method 
of Rivlin and Tator (1978) was used. A bulldog clamp was applied to compress the 
spinal cord for 30 seconds at the lower half of spinal cord segment L3. 
 
After surgery, the rats were given intramuscular injections of 7µg/kg buprenorphin 
(Reckitt & Colman) twice a day for 4 days to avoid allodynia, and 15mg/kg 
trimetoprim sulfa subcutaneously (Intervet International B.V.) to prevent from urinary 
infection. The urinary bladders were emptied manually twice daily until spontaneous 
evacuation was present. 
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Before transplantation, human fetal-derived neurospheres with a diameter between 150 
and 300µm were identified, and 10–12 neurospheres were chosen to give a total 
number of 100,000 cells ± 10% to be transplanted to each rat. The neurospheres were 
kept in NPC medium without growth factors pending transplantation. 
 
In Paper III, hfNPCs (as whole neurospheres) were grafted into the epicenter of the 
lesion site within 15 min (acute transplantation) or 9 days (delayed transplantation) 
after SCI. A subgroup of rats were injected intraperitoneally with 10mg/kg 
cyclosporine A either for the full study period of 6 weeks or the initial 3 weeks, while 
the rest was injected with equivalent volume of saline 6 days per week. In Paper IV, 
transplantation to dorsal spinal cord contusion injuries was performed 9 days after 
lesion. For lateral compression injuries, hfNPCs were transplanted 10 minutes 
(acutely), one week (subacutely) or 7 weeks (chronically) after compression injury. 
 
3.4 Functional assessments (Paper III, IV) 
Locomotor behavior was evaluated using the Basso, Beattie, Bresnahan locomotor 
rating scale (Basso 2004; Basso et al. 1995). In Paper III, the test was carried out prior 
to surgery, 7 and 42 days post-surgery (the end point). In Paper IV, the rats were 
evaluated pre-operatively and then on regular intervals for 18 weeks. 
 
In Paper IV, hindlimb motor function was also assessed using a grid-walk test. To 
assess increased pain sensitivity, pain threshold to pressure to the torso and hindlimbs 
was tested before the injury, immediately after injury and 1, 2, 6, 10 and 18 weeks later, 
using von Frey filaments (Stoelting) ranging from 0.4 to 447 g (Yu et al. 1999). 
 
3.5 Analysis of cell viability and death (Paper I, II, IV) 
In Paper II, cell viability was assessed by resazurin assay, in which the resazurin 
sodium salt (20µg/ml, Sigma) was used as indicator of cell metabolic activity. Results 
are presented as differences in fluorescence intensity of formazan salt. In Paper I, II 
and IV, cell death was evaluated utilizing the necrosis marker 7-AAD and/or 
intracellular apoptosis marker active caspase-3 by flow cytometry. 
 
3.6 Proliferation assay (Paper II) 
Carboxyfluorescein diacetate succinimidyl ester (CFSE)-based proliferation assay, 
depending on a reduction of CFSE fluorescence intensity in successive generations of a 
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proliferating cell population, was performed to evaluate the degree of cell proliferation. 
Briefly, before starting co-cultures, hfNPCs or microglia were labeled with CFSE 
(5µM, Life Technologies) followed the manufacturer’s instruction. hfNPCs and 
microglia were co-cultured for 3 days, then the percentage of divided cells was 
analyzed by flow cytometry. 
 
3.7 Phagocytosis assay (Paper II) 
To analyze the microglial phagocytic activity, microglial cells were labeled by 
fluorescent probe 5-(and 6)-(((4-chloromethyl)-benzoyl) amino)-tetramethyl-rhodamine 
(10µM, Life Technologies). On day 7, cells were incubated with latex beads in 
fluorescent yellow-green (diameter 0.03µm, 1:1000, Sigma) at 37°C for 2 h. Microglial 
mono-cultures were set up as control. Afterwards, cells were harvested and microglial 
uptake of latex beads was analyzed by flow cytometry. 
 
3.8 Immunomodulatory assay (Paper I) 
To investigate how human NPCs affect PBMC sub-populations and cytokine secretion 
in co-cultures, PBMCs, were prepared as described in 3.1.8 and labeled with 
carboxyfluorescein diacetate succinimidyl ester (CFSE, 1µM, Life Technologies) 
according to manufacturer’s instructions, were co-cultured with equal amount of non-
irradiated hESC-NPCs or hfNPCs (5×105 cells/well in 6-well plates) for 3 and 6 days. 
Equivalent cultures were set up in Transwell system with human NPCs and PBMCs 
separated by a semi-permeable membrane (pore size 0.4µm, Millipore-Merck). The 
proportion of CD4+, CD8+, CD4+CD25+ and CD4+CD25+forkhead box P3 (FOXP3)+ 
T cells (a subpopulation previously reported by others to identify induced Tregs 
(Dummer et al. 2012)) and dead T cells in co-cultures recognized by 7-amino-
actinomycin D (7-AAD) was analyzed by flow cytometry. The culture supernatant was 
collected for cytokine analysis at day 6. 
 
To study effects of TGF-β1 and TGF-β2 on PBMC proliferation, 150,000 PBMCs were 
cultured in the presence of phytohaemagglutinin (10µg/ml, Sigma) for 4 days. Human 
recombinant TGF-β1 and TGF-β2 protein (R&D) were added to the culture at 0.01, 0.1, 
1ng/ml and in the case of TGF-β1 also 10ng/ml. The results were analyzed by 
[3H]thymidine incorporation in PBMCs and presented as percentage of PBMC 
proliferation in the presence of phytohaemagglutinin without hTGF-β1 or hTGF-β2 
protein (set as 100%). 
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3.9 Flow cytometry (Paper I-IV) 
To label surface markers, cells were stained with respective antibodies at 4°C for 30 
minutes, washed, resuspended in phosphate-buffed saline and fixed in Cytofix fixation 
buffer (BD Biosciences). FITC-, PE-, PE-Cy5-, PE-Cy7-, PerCP-Cy5.5-, APC- and 
Alexa Fluor 647-conjugated isotype antibodies were used as controls. For intracellular 
staining, cells were fixed and permeabilized with Cytofix/Cytoperm Fixation/ 
Permeabilization Kit (BD Biosciences) following the manufacturer’s instructions. 
Thereafter, the cells were incubated with respective antibodies at 4°C for 30 minutes, 
washed and resuspended in phosphate-buffered saline. To analyze intracellular 
cytokines, Brefeldin A (1:500, BD Biosciences) was added to the culture medium 
during the last 6 hours to block cytokine secretion, followed by intracellular staining. 
All antibodies used in flow cytometry in this thesis are listed in Table 1. Flow 
cytometry data were collected using a FACScalibur (Becton and Dickinson) and data 
analysis on percentage of positive cells and mean fluorescence intensity was performed 
with the software FlowJo (Tree Star, Inc.). 
 
Table 1. Antibodies used in flow cytometry (to be continued) 
Conjugated antibodies 
Antibodies Fluorescence 
conjugated 
Clone Manufacturer Paper 
CD3 FITC UCHT1 Dako I 
CD4  APC RPA-T4 BD Biosciences I 
 FITC RPA-T4 BD Biosciences III 
CD8 PE RPA-T8 BD Biosciences I, III 
 PE-Cy7 RPA-T8 BD Biosciences I 
CD11b PE-Cy7 M1/70 BD Biosciences III 
CD15 PC5 80H5 Beckman Coulter I 
CD24 PE ML5 BD Biosciences I 
CD25 PE M-A251 BD Biosciences I 
CD29 PE-Cy5  MAR4 BD Biosciences I 
CD31  FITC WM59 BD Biosciences I 
CD40 FITC 5C3 BD Biosciences I, II, III 
 AlexaFluor647 5C3 Biolegend I 
CD44 PE 515 BD Biosciences I 
CD45 APC HI30 BD Biosciences III 
CD54 PE HA58 BD Biosciences I 
CD56 PE MY31 BD Biosciences I 
CD58  FITC 1C3 BD Biosciences I 
CD68 AlexaFluor647 Y1/82A BD Biosciences III 
CD80 FITC L307.4 BD Biosciences I, II, III 
 PE-Cy7 L307.4 BD Biosciences I 
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Table 1. Antibodies used in flow cytometry (continued) 
Antibodies Fluorescence 
conjugated 
Clone Manufacturer Paper 
CD86 FITC 2331 BD Biosciences I, II, III 
 AlexaFluor647 IT2.2 Biolegend I 
CD163 AlexaFluor647 RM3/1 Biolegend II 
CD184 PE 12G5 BD Biosciences I 
CD200 PerCP-Cy5.5 MRC OX-104 BD Biosciences II 
CD200R PE OX-108 Biolegend II 
CD206 AlexaFluor647 15-2 Biolegend II 
HLA-I PE W6/32 Dako I, III 
HLA-II FITC CR3/43 Dako I, II, III 
HLA-DR PE G46-6 BD Biosciences I, III 
Stage-specific 
embryonic antigen 4 
PE MC-813-70 Millipore-Merck I 
Polysialylated-neural 
cell adhesion molecule 
(PSA-NCAM) 
PE 2-2B Miltenyi Biotec I, II 
A2B5 PE 105-HB29 Miltenyi Biotec I, II 
Nestin PerCP-Cy5.5 aa. 402-604  BD Biosciences I, II 
GFAP PE Cow spinal cord 
homogenate 
BD Biosciences I, II 
β-tubulin III AlexaFluor647 rat brain 
microtubules 
BD Biosciences I, II 
FOXP3 PerCP-Cy5.5 236a BD Biosciences I 
TGF-β1 PE 9016 R&D I, II 
7-AAD   BD Biosciences I, II 
Active Caspase-3 PE C92-605 BD Biosciences II, IV 
Unconjugated primary antibodies 
Antibodies Isotype Concentration Manufacturer Paper 
TRA-1-60 Mouse IgM 1:500 Millipore-Merck I 
TRA-1-81  Mouse IgM 1:200 Santa Cruz I 
Brachyury Rabbit IgG 1:200 Sigma I 
Ki67 Mouse IgG 1:100 Dako I 
TGF-β2 Rabbit IgG 1:200 R&D II 
Unconjugated secondary antibodies 
Antibodies Concentration Manufacturer Paper 
Anti-mouse FITC IgM  1:200 BD Biosciences I 
Anti-mouse FITC IgG 1:200 BD Biosciences I 
Anti-rabbit FITC IgG 1:200 BD Biosciences I, II 
Isotype antibodies 
Isotype Fluorescence conjugated Manufacturer Paper 
IgM PE Miltenyi Biotec I, II 
IgG FITC/PE/PE-Cy5/PE-Cy7/PerCP-
Cy5.5/APC/ AlexaFluor647 
BD Biosciences I, II 
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3.10 Immunochemistry (Paper I-IV) 
In Paper I, ten to fifteen intact neurospheres of hESC-NPCs and hfNPCs were 
collected, fixed in 4% paraformaldehyde for 15 minutes at room temperature, treated 
with 30% sucrose over night at 4°C, mounted in Tissue-Tek mounting medium (Sakura 
Finetek), frozen on dry ice and sectioned at a thickness of 5µm. In Paper II, cells 
cultured on cover slips were fixed with 4% paraformaldehyde for 15 minutes at room 
temperature and rinsed in phosphate-buffered saline. In Paper III and IV, the rat 
spinal cord tissue was fixed for 90 min-2 hours, rinsed and cryopreserved in 10-20% 
sucrose at 4°C for at least 24 h. The spinal cords were sectioned at 10µm in a cryostat 
and mounted on gelatin-coated slides. 
 
Cells or tissue sections were pre-incubated with serum at room temperature, incubated 
with primary antibodies overnight at 4°C, rinsed before incubation with the secondary 
antibodies at room temperature. All antibodies used in immunochemistry in this thesis 
are listed in Table 2. The cell nuclei were stained with Hoechst 33342 (1:400, Life 
technologies) prior to mounting in PVA-DABCO (9.6% polyvinyl alcohol, 24% 
glycerol, and 2.5% 1,4-diazabicyclo (2.2.2) octane in 67 mM Tris-HCl, pH 8.0). The 
images were acquired in a fluorescence microscope (Axiophot, Zeiss) and documented 
using a CCD camera (ORCA-ER) together with the Openlab software 3.1.7 for 
Macintosh (Improvision), or using an inverted microscope Axiovert 200M (Carl Zeiss 
MicroImaging GmbH) connected to a LSM510 META confocal unit. 
 
3.11 Quantitative histological analysis (Paper III, IV) 
In Paper III, to determine the extent of the microglial and macrophage response, the 
mean intensity of the ED1 immunoreactivity was quantitatively evaluated using Image-
Pro Plus software (Media Cybernetics) and calculated as luminosity units per tissue 
area. In Paper IV, the proportion of human donor cells expressing phenotype markers 
and the number of survived rat spinal cord neurons were evaluated by counting 
immunoreactive cells in 4–6 fields of view at 40× magnification, and calculated with 
Abercrombie correction. 
 
3.12 Enzyme-linked immunosorbent assay (ELISA) (Paper I, II) 
The ELISA reagents and components for TNF-α, IL-6, IL-10, TGF-β1, TGF-β2, 
BDNF, GDNF and NT-3 were purchased from R&D. The experimental procedure was 
performed according to the manufacturer’s instructions with Tris-buffered saline as  
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Table 2. Antibodies used in immunochemical procedures 
 
Primary antibodies 
Antibodies Species Concentration Manufacturer Paper 
Nanog Goat 1:200 R&D I 
Brachyury Rabbit 1:200 Sigma I 
α-fetoprotein Goat 1:200 Santa Cruz I 
Pax-6 Rabbit 1:200 Santa Cruz I 
Nestin Mouse 1:200 Millipore-Merck I, II 
 Rabbit 1:400/1:250 Millipore-Merck I, IV 
β-tubulin III Mouse 1:800 Covance I, II 
 Rabbit 1:1200 Nordic Biosite IV 
GFAP Rabbit 1:500 Dako I 
 Mouse 1:50 Abcam II 
 Mouse 1:200,000 Sternberger 
Monoclonals 
IV 
Ki67 Mouse 1:100 Dako I 
Iba-1 Rabbit 1:200 Wako II 
ED1 Mouse 1:200 AbD Serotec III 
Synapse-associated 
protein 102 (SAP102) 
Rabbit 1:200 Almone labs III 
Heat shock protein 27 Rabbit 1:1500 Medical & 
Biological 
Laboratories 
III, IV 
Human nuclear protein Mouse 1:150 Millipore-Merck IV 
Proliferating cell 
nuclear antigen 
Mouse 1:100 Cell Signaling 
Technology 
IV 
Microtubule-associated 
protein 2 
Rabbit 1:50 Millipore-Merck IV 
Secondary antibodies 
Anti-goat Alexa Fluor 
488 
Donkey 1:1200 Life Technologies I 
Anti-mouse Alexa 
Fluor 488 
Goat 1:1200 Life Technologies I, II, III 
Anti-rabbit DyLight 
549 
Donkey 1:2400 Jackson 
ImmunoResearch 
Laboratories 
I 
Anti-mouse Cy3 Goat 1:2400 Jackson 
ImmunoResearch 
Laboratories 
I 
Anti-rabbit Cy3 Goat 1:2400 Jackson 
ImmunoResearch 
Laboratories 
I, II, III 
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wash buffer. In Paper II, QuantaRed fluorescent substrate (Thermoscientific) was used 
instead of a colorimetric substrate in the assays for TNF-α, IL-10, GDNF and NT-3.The 
culture supernatant were processed in triplicate samples. The analysis of 96-well plates 
was achieved in a TECAN Safire2 microplate reader (Männedorf) at 540 nm. 
 
3.13 Statistical analysis (Paper I-IV) 
Analysis of differences among groups was performed by either parametric (t-test or 
One-way ANOVA) or non-parametric tests (Mann-Whitney test or Kruskal-Wallis test) 
depending on whether the data were normally distributed or not. In Paper III, Chi-
square test for independent groups was used to evaluate differences in rejection ratios 
between experimental groups. All statistical analysis was performed with Instat 3.0 
(GraphPad Software Inc.) or StatView 4.5 (Abacus Concepts) for Macintosh. P-values 
less than 0.05 were considered statistically significant. Data are shown as mean ± mean 
standard error (Paper I-III), mean ± standard deviation (Paper IV) or median ± 
percentiles (25%-75% and 5%-95%, Paper II). 
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4 RESULTS AND DISCUSSION 
4.1 Characterization of human NPCs (Paper I-IV) 
We compared cellular characteristics of human NPCs in vitro cultured under equivalent 
conditions but originating from different origins. We observed that hfNPCs and hESC-
NPCs expressed similar amounts of a number of markers, such as neuronal progenitor 
marker PSA-NCAM, CD29 (reported to modulate NPC survival, migration, 
proliferation and differentiation (Campos 2005)), CD44 (known to be expressed on 
glial progenitors and astrocytes (Liu et al. 2004)) and neural cell adhesion molecule 
CD56 (Paper I). In contrast, hfNPCs presented a higher percentage of cells expressing 
the glial progenitor marker A2B5 and the neural cell growth and migration modulator 
CD184 than hESC-NPCs. We further showed that, when hfNPCs were cultured with 
mitogens present approximately 92% were nestin+, while 56% were GFAP+ of the total 
hfNPCs population. Only 6% of the hfNPCs were β-tubulin III+. After differentiation 
for 7 days (Paper II), the percentage of hfNPCs expressing nestin decreased, while the 
subpopulation of cells positive for β-tubulin III and GFAP was significantly increased, 
These findings indicated that hfNPCs were able to differentiate into both neuronal and 
glial lineages in vitro. 
 
Twenty weeks post transplanttion into SCI rats (Paper IV), hfNPCs positive for the 
early neuronal marker β-tubulin III and the more mature neuronal marker microtubule-
associated protein-2 comprised less than 10% of the total donor cell population. In all 
groups, the majority (80–90%) of transplanted hfNPCs differentiated into astrocytes 
(GFAP+ cells), which previously have been associated by others with allodynia 
(Hofstetter et al. 2005; Macias et al. 2006). In our case, no allodynia was observed after 
hfNPC transplantation despite astrocyte differentiation, suggestion it is not astrocyte 
differentiation in general that is the cause for this severe side effect. 
 
Proteins involved in antigen processing and presentation were studied on hESC-NPCs 
and hfNPCs. Both hESC-NPC and hfNPC populations presented high percentages of 
HLA-I+ and CD58+ cells, but expressed low proportions of co-stimulatory molecules 
CD80 and CD86, as well as adhesion molecule CD54. Cells expressing the co-
stimulatory molecule CD40 were more abundant among hfNPCs than hESC-NPCs. 
However, in neither cell type, no HLA-II+CD40+CD80+CD86+ cells were detected by 
flow cytometry. The expression pattern of these immune-related markers indicates that 
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the antigen presentation to induce naïve T cells is limited due to the lack of expression 
of HLA-II, adhesion and co-stimulatory molecules on the same cells. Moreover, none 
of these molecules was affected by stimulation of pro-inflammatory cytokine in neither 
human NPC population, further supporting the hypothesis that hESC-NPCs and 
hfNPCs have a limited risk of triggering an immune response, even in an ongoing 
inflammatory milieu, such as a SCI. 
 
It has previously been demonstrated that the duration of in vitro propagation of 
human NPCs may lead to changes in cellular composition even under equal culture 
conditions (Piao et al. 2006). The expression pattern of immune-related proteins on 
hfNPCs with “short” (P0) and “long” (P5) in vitro-expansion time was investigated. P0 
hfNPCs expressed low percentage of HLA-I and HLA-II (11% and 4%) compared to 
P5 cells (85% and 35%). The co-stimulatory molecules CD40, CD80 and CD86 were 
undetectable at P0, while at P5 expressed in up to 5% of hfNPCs. The observed 
increased expression of HLA, co-stimulatory and adhesion molecules (Akesson et al. 
2009; Odeberg et al. 2005) on hfNPCs allows them at least in theory, despite an initial 
limited risk, to act as antigen presenting cells with direct antigen presentation to elicit 
the host immune reaction. 
 
Cytokines secreted by human NPCs may affect the host immune response in allogeneic 
neural cell therapy. Compared to hESC-NPCs, unstimulated hfNPCs secreted more 
TGF-β1 (in Paper I), a factor involved in the maintenance of immune tolerance and T-
cell homeostasis (Bommireddy and Doetschman 2007) and also reported to balance the 
immunogenicity of FBr-NPCs (Ubiali et al. 2007). hfNPCs also released higher level of 
TGF-β2 (in Paper I). Increased TGF-β2 levels may polarize naïve T cells toward a 
regulatory function that could in turn mediate suppression antagonizing adaptive 
immune responses (Robertson et al. 2007). In addition, the release of TGF-β1, TGF-β2 
and IL-10 by hESC-NPCs increased under inflammatory conditions, suggesting that the 
immunomodulatory potential of hESC-NPCs might be promoted when they encounter 
an inflammatory environment as in neurodegenerative diseases and CNS trauma. 
 
4.2 Survival of human NPCs after SCI transplantation (Paper III, IV) 
Human neural donor cells have been reported to respond differently to host 
environment cytokines depending on regional origin (Johansson et al. 2008). However, 
no difference was observed in number of survived donor cells between SC-NPCs and 
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FBr-NPCs transplanted SCI rats (Paper IV). When SC-NPCs in vitro expanded for 5 
passages were grafted acutely into immunocompetent severe SCI rats, no surviving 
donor cells were found in the injured spinal cords 6 weeks after transplantation, while 
SC-NPCs implanted at P0 were still present in 3/5 cases. In the presence of the 
immunosuppressant cyclosporine A, no difference was observed in the survival of SC-
NPCs implanted at P0 and P5. The lower rejection ratio for short-term in vitro 
expanded SC-NPCs may be explained by the fact that fewer NPCs expressed HLA and 
co-stimulatory molecules after short in vitro culture time (Akesson et al. 2009; Odeberg 
et al. 2005). 
 
Levels of potentially toxic cytokines in the injured spinal cord increase rapidly after 
injury (Nakamura et al. 2003; Pineau and Lacroix 2007), which may harm the donor 
cells. However, this has previously not been systematically investigated. To address 
this issue, donor human NPCs were grafted at different time point post-injury and the 
donor survival in the host spinal cord was analyzed. No difference was found on the 
survival of acutely or delayed grafted SC-NPCs 6 weeks after transplantation in the 
moderate SCI rats, in the presence of immunosuppressant (Paper III). The survival of 
human donor cells in the host spinal cord long term (20 weeks) after transplantation 
was further investigated (Paper IV). Although there was no significant difference 
among groups with acute, subacute or chronic transplantation, the mean number of 
human cells was highest in the group transplanted acutely. Hence, the acutely injured 
spinal cord does not seem to be a more hostile milieu for grafted human NPCs than that 
in the subacute or chronic phase. The reason may be that NPCs are less sensitive to 
apoptotic stimuli, as has been found for other neural stem cells (Tamm et al. 2004). To 
further address how the host milieu may influence donor neural cells, host rats were 
exposed to severe or moderate contusion SCI in Paper III. In the absence of 
immunosuppression, acutely grafted SC-NPCs was fully rejected in all hosts 6 weeks 
post-injury in the severely injured hosts, while SC-NPCs implanted with a delay of 7 
days into moderate SCI survived in 4/6 rats, suggesting that acute severe injury with a 
more intense inflammatory response is more detrimental for the donor NPCs. Further 
studies are needed to provide direct evidence how the SCI severity influences the fate 
of donor cells, with the same in vitro expanded duration and transplantation timing of 
the donor cells. 
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Furthermore, the number of donor human cells 20 weeks after transplantation into 
immunosuppressed SCI hosts greatly exceeded the number of transplanted NPCs, in 
some animals as much as 9-fold. This contrasts to some earlier transplantation studies 
(Hofstetter et al. 2005; Karimi-Abdolrezaee et al. 2006), while other report similar 
proliferation after transplantation of human neural stem cells to chronic SCI in mice 
(Salazar et al. 2010). We have previously reported that cell death in transplanted 
neurospheres is surprisingly low, and that some low degree of proliferation of the 
grafted SC-NPCs continues, but peaks already at 1 day post transplantation and then 
declines (Emgard et al. 2009). This results in a net increase of human cells. 
 
4.3 Host lymphocyte response to human NPCs (Paper I, III) 
The presence of HLA, co-stimulatory and adhesion molecules on human NPCs implies 
a risk for recognition and rejection by non-compatible immune cells after 
transplantation. In the in vitro allogeneic co-cultures of human NPCs and PBMCs, 
hESC-NPCs triggered PBMC proliferation in a dose-dependent manner, and the 
response was not affected by IFN-γ and/or TNF-α (Paper I). In contrast, hfNPCs tested 
under equivalent conditions did not elicit an allogeneic PBMC proliferation, which is 
consistent with previous findings on hfNPCs and their differentiated derivates 
(Akesson et al. 2009; Odeberg et al. 2005). Noteworthy is the report by, Laguna Goya 
et al., that hfNPCs triggered a delayed proliferative response of allogeneic T cells after 
14 days in vitro (Laguna Goya et al. 2011). Despite the fact that hESC-NPCs can 
trigger PBMC proliferation already after 6 days in co-culture, neither hESC-NPCs nor 
hfNPCs further enhanced a PBMC alloresponse triggered by a third party of allogeneic 
PBMCs, but instead hindered the proliferative response. This effect also occurred in a 
dose-dependent pattern and was altered by the addition of pro-inflammatory cytokines 
in the cultures. Mesenchymal stem cells are known to have strong immunesuppressive 
properties on immune cells and can counteract graft versus host disease in clinical 
hematopoietic stem cell therapies (Le Blanc et al. 2008), which requires activation by a 
pro-inflammatory environment to exert the immunomodulatory effects (Engela et al. 
2012). Similarly, an activated immunosuppressive process by hESC-NPCs or hfNPCs 
was found in the ongoing alloresponse milieu (Paper I). 
 
Transplantation of syngeneic mouse NPCs in a focal SCI increased the proportion of 
Tregs (Cusimano et al. 2012), which are known to promote antigen-specific peripheral 
tolerance by suppressing the activation and expansion of reactive effector cells. In 
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Paper I, both hESC-NPCs and hfNPCs up-regulated Tregs, defined as the proportion of 
CD4+CD25+FOXP3+ T cells among CD4+ T cells, after 6 days co-culture with direct 
cell-cell contact but not in the transwell system. This suggests that cell-cell contact 
between human NPCs and allogeneic PBMCs is an important mechanism to up-
regulate CD4+CD25+FOXP3+ T cells. The production of immunomodulatory cytokines 
such as TGF-β1 is one of the major pathways through which FOXP3+ Tregs exert their 
regulatory function. Bommireddy et al. reported that FOXP3+ Tregs in TGF-β1-/- mice 
were not able to inhibit the activation of CD4+CD25+ T cells, suggesting the signal 
from FOXP3 alone in Tregs is not enough for their action (Bommireddy et al. 2009). It 
seems as if TGF-β1 is required for the suppressive function of Tregs. In Paper I, the 
release of TGF-β1 was coherent with the up-regulation of CD4+CD25+FOXP3+ T cells 
in the presence of hfNPCs in direct contact with PBMCs, but not hESC-NPCs. The 
PBMC proliferative response could be reduced by the exogenous addition of TGF-β 
protein. Furthermore, the participation of TGF-β1 antibody at least partly interfered and 
resulted in a higher proliferative response in co-cultures of PBMC and human NPCs. 
Taken together, these events suggest that TGF-β1 released at high enough levels by 
human NPCs may support the induced FOXP3+ Treg population to exert their 
suppressive effects. 
 
The CD4+, CD8+ or CD25+ populations in peripheral blood and spleen of the severe 
injured xenogeneic hosts in an in vivo SCI model were not observed to be affected by 
grafted hfNPCs. Interestingly, a group of CD4+CD8+ cells, which have been reported to 
participate in antigen exposure and lymphocyte maturation (Kenny et al. 2004) as well 
as to play a protective role in clinical acute graft versus host disease (Eljaafari et al. 
2013), was found in the rodent hosts. When PBMCs from moderate SCI rats and 
equivalent hfNPCs as grafted in vivo were co-cultured in an in vitro MLC assay, the 
stimulation index (related to the PBMC proliferative response) was significantly higher 
in all lesioned groups with or without donor hfNPCs, compared to the normal control. 
However, no significant difference could be observed in the lymphocyte populations 
among the SCI groups despite a known host rejection response in some of the groups. 
 
4.4 Host microglial/macrophage response to human NPCs (Paper II, III) 
Microglia are known to be the primary mediators of the innate immune response in the 
CNS, playing an important role in immune surveillance and homeostasis under normal 
conditions (Kettenmann et al. 2011). Upon injury, microglia are rapidly activated and 
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become selectively directed to the injured site (Hanisch and Kettenmann 2007). In 
Paper II, a human allogeneic setting was utilized, by seeding “non-activated” microglia 
with hfNPCs early during differentiation, to evaluate their effects on each other. The 
proliferation and phagocytic activity of human microglia were increased in the presence 
of hfNPCs, as well as the proportion of microglia positive for M1-marker HLA-II or 
M2-marker CD206. These data suggested that hfNPCs can influence the degree of 
microglial activation and functional activity in vitro, and that different microglial 
phenotype can emerge under these human co-culture conditions. On the other hand, co-
culture with microglia increased the proliferation of hfNPCs, which is in accordance 
with findings from rodent studies (Cacci et al. 2008; Mosher et al. 2012), where 
conditioned medium from untreated microglia were added to NPCs. hfNPCs in co-
cultures with human microglia presented a higher percentage of nestin, and a lower 
proportion of PSA-NCAM, A2B5 and GFAP positive cells compared to mono-cultures. 
This observation suggested that the presence of microglia inhibited hfNPC maturation 
and differentiation with regard to both neuronal or astroglial destiny. These 
observations could be partially explained by the presence of IL-6 released by microglia 
in the co-cultures as suggested by others (Ideguchi et al. 2008). Thus, microglia might 
play a role as a determinant of NPC destiny in human allogeneic setting. 
 
Glial cells and neurons are reported to express a range of neuroimmune regulatory 
proteins (NIRegs), such as CD200, to counteract neurotoxic effects of innate immune 
molecules (Grimsley and Ravichandran 2003; Neumann 2001). NIRegs in analogy to 
Tregs, are involved in silencing and reshaping an adverse innate immune response, and 
in polarizing microglia towards a protective phenotype, to limit inflammatory reactions 
in the injury site (Griffiths et al. 2010). CD200R, structurally closely related to CD200, 
is mainly expressed on myeloid cells such as microglia and delivers an inhibitory signal 
after ligation to CD200 (Jenmalm et al. 2006). The CD200-CD200R interaction 
provides a negative cell-cell contact dependent regulatory signal for microglia and 
protects neural cells in neurodegenerative diseases (Chitnis et al. 2007; Koning et al. 
2009; Walker et al. 2009; Zhang et al. 2011). Therefore, it is reasonable to assume that 
a CD200-CD200R interaction plays an important role in regulating microglial activity 
and restricting neuroinflammation. In the allogeneic hfNPC-microglia co-cultures, not 
only did a larger proportion of hfNPCs express CD200, but also the expression of 
CD200R on microglia was up-regulated. As a result, the opportunity for a CD200-
CD200R interaction between hfNPCs and microglia was increased, which may limit 
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deleterious neuroinflammation caused by microglia. Blocking the CD200-CD200R 
interaction can lead to decreased TGF-β expression (Clark et al. 2008; Memarian et al. 
2013), in other words, CD200-CD200R interaction may support the release of TGF-β. 
In the allogeneic co-cultures, the TGF-β2 level in supernatant was higher than in 
monocultures, and the subpopulation of TGF-β1 expressing hfNPCs was significantly 
larger in the presence of microglia. The increased TGF-β release might be due to an 
enhanced CD200-CD200R interaction between hfNPCs and human microglia. In 
addition, the increased level of TGF-β may contribute to the enhanced phagocytic 
activity of microglia in co-cultures, as TGF-β has been shown to enhance survival and 
activity of phagocytic microglia (Ryu et al. 2012; Tichauer and von Bernhardi 2012). 
The up-regulation of anti-inflammatory M2-marker CD206 might be due to the 
elevated release of TGF-β2, which may help to polarize microglia towards an anti-
inflammatory phenotype and to influence the antigen-presenting functions of microglia 
(Paglinawan et al. 2003; Siglienti et al. 2007). 
 
In Paper III, the host microglial and macrophage response to xenotransplanted hfNPCs 
was evaluated in a contusion SCI animal model through the quantitative analysis of 
ED1 immunoreactivity. ED1, equivalent to CD68 in humans, is a single chain 
glycoprotein expressed on lysosomal membranes of myeloid/macrophage cells and 
highly expressed by phagocytic cells (Damoiseaux et al. 1994). In the normal spinal 
cords, the ED1 immunoreactivity was very low with no observed activated microglia 
and macrophages present. In the injured spinal cord, numerous amoeboid shaped and 
intensely immunoreactive ED1+ cells were observed. In hfNPC transplanted group, the 
ED1 immunoreactivity in the moderate injury epicenter was significantly decreased 
suggesting a reduced microglial/macrophage inflammatory response locally in the SCI 
epicenter compared to non-grafted rodents. No difference was observed between 
hfNPC-P0 and hfNPC-P5 grafted groups, or between acute and delayed transplanted 
groups. Similarly, donor neural cells have been reported to decrease CNS inflammation 
by immunomodulatory effects in EAE (Einstein et al. 2007) and stroke models (Mine 
et al. 2013). With the observed difference in the microglial/macrophage reaction 
between in vivo xenografted and non-grafted groups, the host microglial response was 
further investigated in a human allogeneic setting by employing an in vitro human 
organotypic spinal cord slice culture model. The immunomodulatory effect by hfNPCs 
on activated microglia was confirmed in human allotransplantation model mimicking 
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human allogeneic neural cell therapy. Important to note, allografted hfNPCs per se, in 
the sham control slices, did not trigger sustained microglial activation. 
 
Furthermore, microglia are known to play an active role in the development of mature 
synapses (Schafer et al. 2013). Activated microglia could stimulate either 
neosynaptogenesis (Bessis et al. 2007) or induce synaptic stripping (Kettenmann et al. 
2013). An attempt was made to evaluate the expression and distribution of the post-
synaptic protein SAP102 at the site of microglia (ED1+) accumulation in the lesioned 
epicenter of moderate injured spinal cord, but no sign of changed immunoreactivity in 
SAP102 could be observed between grafted and non-grafted groups. Further study is 
needed to investigate the complex interaction between microglia and the neuronal 
synapse. 
 
4.5 Host neuroprotection by human NPCs (Paper IV) 
In both contusion and compression SCI models, the hindlimb motor function of rats 
was significantly improved by SC-NPCs transplanted subacutely. The effect of acutely 
transplanted SC-NPCs was even more pronounced in the compression injury compared 
to the contusion injury model, reaching a difference between transplanted and non-
transplanted groups of more than 4 points of the Basso, Beattie, Bresnahan locomotor 
rating scale score. In contrast, transplantation at the chronic stage was without 
beneficial effect. A lack of treatment effect was also seen in animals transplanted 
subacutely with FBr-NPCs, which contrasts to a previous report with observed similar 
functional improvement with rodent SC-NPCs and FBr-NPCs in a SCI contusion 
model (Watanabe et al. 2004). 
 
The therapeutic effect of SC-NPCs declined when the delay between injury and 
transplantation increased, suggesting that neuroprotection is an important mechanism 
of the grafted NPCs to rescue dying neurons in the injured spinal cord. All SCI rats 
suffered a major loss of neurons in the injured part of the cord. In the acutely grafted 
rats showing the best functional outcome, the number of surviving host neurons in the 
injured spinal cord was almost 3 times as many as in non-transplanted rats. In the hosts 
with subacute transplantation, the second best functional outcome was paralleled by 
twice as many surviving host neurons as in the control group. The other groups, which 
did not achieve better functionality than the control group, also did not contain more 
surviving host neurons than the control group. This strongly indicated that 
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neuroprotection is one of the main therapeutic effects of the grafted NPCs. The cell 
type(s) responsible for the protective effect are most likely the immature NPCs, which 
mainly are present during the 7–9 days therapeutic window, while differentiation takes 
place weeks-months after grafting. Accordingly, the ratios of differentiated cell types 
were not correlated to functional improvement. 
 
The common experimental design studying transplantation of human cells constitutes a 
xenotransplantation, in contrast to the allogeneic situation in clinic. Even if graft 
rejection can be avoided (as in the clinic) by using immunosuppressant or here 
experimentally by utilizing genetically immunodeficient animals, the resulting 
immunemodulation may interfere with mechanisms studied. To address this, a 
contusion injury model in a human organotypic spinal cord slice culture system was 
used to offer an allotransplantation-like situation. The analysis of active caspase-3-
positive host cells, in the injured human fetal spinal cord slices, showed that human 
NPC transplantation prevented the caspase-3-dependent apoptosis, demonstrating a 
strong protective effect. 
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5 CONCLUSIONS 
The overall aim of this thesis project was to improve the understanding of host 
responses and interactions between host and donor cells in human neural cell therapy 
after SCI. 
 
The immunocompetence, immunogenicity and interactions of two potential human 
NPCs with human lymphocytes were studied. hESC-NPCs, but not hfNPCs, triggered 
an allogeneic response in a dose-dependent manner. This suggests that in the naïve non-
stimulated encounter between incompatible donor NPCs and host lymphocytes, hESC-
NPCs are more immunogenic than hfNPCs. Despite the fact that hESC-NPCs trigger 
lymphocyte proliferation, neither hESC-NPCs nor hfNPCs enhanced an established 
lymphocyte alloresponse. In contrast, both types of human NPCs reduced this 
proliferative response. Our findings indicate that both human fetal and ESC-derived 
NPCs have immunomodulatory effects, and can counteract an activated ongoing host 
alloreaction. 
 
Both types of human NPCs increased the pool of regulatory T cells, when in direct cell-
cell contact during cultures. However, non-stimulated hfNPCs (without presence of the 
cytokines TNF-α or IFN-γ) secreted more TGF-β than hESC-NPCs. Furthermore, there 
was an increased level of TGF-β1 in the media and present in the cells in co-cultures of 
lymphocytes and hfNPCs compared to co-cultures with hESC-NPCs. Lymphocyte 
proliferation could be reduced by exogenous addition of TGF-β. In addition, TGF-β1 
antibody treatment resulted in a higher lymphocyte proliferative response in co-cultures 
with hfNPCs. Taken together, these results suggest that TGF-β1 induced by hfNPCs 
may exert suppressive effects, possibly via an induced FOXP3+ regulatory T cell 
population. We conclude that human NPCs of different origin display similarities but 
also significant differences in their immunocompetence and interaction with allogeneic 
lymphocytes. These differences may affect a host response, and potentially the outcome 
of neural cell therapy. 
 
With the aim to mimic a naïve encounter of donor human NPCs with allogeneic 
microglia, we performed another set of co-cultures. In the presence of hfNPCs, the 
proliferation and phagocytic activity of human microglia were increased, as well as the 
proportion of microglia positive for M1-marker HLA-II or M2-marker CD206. These  
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Fig.2. A schematic summary and my hypothesis concerning human NPC and host cell 
interactions of relevance for neural cell therapy in SCI. (A) The immunogenicity of hESC-
NPCs and hfNPCs and their interactions with human lymphocytes in vitro. Both hESC-NPCs 
and hfNPCs expressed HLA, co-stimulatory and/or adhesion molecules, and increased the pool 
of Tregs. hESC-NPCs, but not hfNPCs, triggered allogeneic lymphocyte proliferation, but both 
types of human NPCs reduced an ongoing lymphocyte alloresponse. TGF-β1 induced by 
hfNPCs may exert suppressive effects, possibly via induced FOXP3+ Tregs. (B) Interplay 
between hfNPCs and human microglia in vitro. The presence of hfNPCs increased the 
proliferation, phagocytosis of human microglia, as well as the proportion of HLA-II+ or CD206+ 
microglia. Co-culture with microglia increased the proliferation of hfNPCs, but hindered their 
differentiation. The CD200-CD200R interaction was enhanced in the co-culture of hfNPCs and 
human microglia. (C) The immunomodulatory and neuroprotective effects of hfNPCs in vivo. 
Transplanted hfNPCs in the injured spinal cord presented an immunomodulatory effect by 
decreasing post-lesion macrophage/microglial activation. Finally, hfNPCs exerted a 
neuroprotective effect by enhancing the survival of the host neural cells in the injured spinal 
cord. 
 
data suggest that transplanted hfNPCs can influence the activation and functional 
activity of host microglia, and that different microglial phenotype can emerge. Co-
culture with microglia also increased the proliferation of hfNPCs but hindered their 
differentiation with regard to both neuronal or astroglial fate. Thus, the interplay 
  54 
between human NPCs and microglia significantly affected their respective proliferation 
and phenotype. Furthermore, in in vivo studies on hfNPC xenotransplantation, host 
microglial/macrophage ED1 immunoreactivity was significantly decreased at the lesion 
epicenter after a moderate injury compared to non-grafted cases. This finding was 
confirmed in a human allogeneic setting by employing an in vitro human organotypic 
spinal cord slice culture model. From our in vitro and in vivo studies we conclude that 
cell therapy using human NPCs as donor, in addition to cell replacement, also can 
reduce the host microglial response to SCI. 
 
Finally, hfNPC xenotransplantation was performed in both contusion and compression 
SCI in rodents. In both SCI models, human spinal cord-derived NPC transplantation 
within 9 days after lesion significantly improved host functional outcome. The 
improved function correlated with an increase of host neurons in the spinal cord. A 
neuroprotective effect of human NPCs was further confirmed in a human allogeneic 
setting using human organotypic spinal cord slice cultures. These results from multiple 
SCI models as well as in two different species, including human tissue, indicate a 
robust neuroprotective effect by human donor NPCs in SCI. 
 
Increased understanding of the immunocompetence and immunomodulatory effects, 
as well as the neuroprotective potential of transplanted neural cells is of significant 
importance since it can improve matching of donor and host, the choice of time point 
for intervention and the design of immunosuppressive treatments for clinical neural 
cell therapy in SCI. 
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